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Modern medicine would benefit from the pursuit of new, more specific and easier
to implement diagnosis tools. In recent years, Raman scattering, surface-enhanced
Raman scattering and fluorescence spectroscopy have proven to be successful diag-
nostic techniques for a wide range of diseases including atherosclerosis, kidney stones,
bone diseases, diabetes, and a wide collection of neoplasms. Optical spectroscopy has
several advantages over more traditional diagnostic methods (i.e., histopathology,
quantitative PCR, etc.) such as faster data analysis, nonspecific sample preparation,
nonspecific labels/reagents/antibodies usage requirements, and immediate on-site
implementation.
In the present work, label-free in vitro fluorescence and surface enhanced Raman
scattering (SERS) spectroscopy have been used to differentiate between blood cells
of patients affected with myeloproliferative neoplasms (MPN) and those of healthy
subjects. The SERS technique has also been applied to hemoglobin variants as well
as to serum obtained from patients affected with chronic heart failure who positively
or negatively responded to the seasonal influenza vaccine.
We found that spectral ratios of the background fluorescence intensity that ac-
companies the SERS spectra of granulocytes serve as excellent markers for the pres-
ence of MPNs. In addition, we also found expression dysregulation of two hy-
poxia induced factor regulated genes, which correlates with our results obtained
by SERS spectroscopy assay in MPN patients and supports the presence of the
Warburg effect in MPNs. We hypothesize that SERS measures metabolic change in
granulocytes through two possible mechanisms: (i) Changes in dielectric properties
of the environment surrounding the silver-cell interface; and (ii) changes in flavin
adenine dinucleotide concentrations, which in turn changes the relative contribution
of the autofluorescence to the emission spectrum. These hypotheses are supported by
SERS measurement of 2-deoxy-D-glucose incubated granulocytes, where the emission
spectra show a similar behavior as observed in the SERS spectra of controls and
patients.
Using SERS spectroscopy in combination with multivariate analysis (e.g., princi-
pal component analysis) and classification algorithms (e.g., support vector machines),
we are able to distinguish among hemoglobin variants S, C and E and traits FS and
FE, as well as seasonal influenza vaccine responders and nonresponders within a
population of patients suffering from chronic heart failure.
The results presented here may have an extraordinary impact on the diagnos-
tics of patients having Myeloproliferative Neoplasms, as well as on the health care
management of patients affected with hemoglobinopathies and chronic heart failure.
iv
A mis papa´s, Martha y Benito, que me han dado amor y apoyo incondicional todos
los d´ıas de mi vida
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INTERACTION OF LIGHT WITH MATTER
Assays that offer better detection of a disease or a dysfunction are highly desired.
Such assays should provide prompt, quantitative and accurate assessments of the
disease while ideally being inexpensive, noninvasive, reagent free and easily and
quickly implementable. Optical spectroscopy techniques have fulfilled some of these
requirements and in contrast with current diagnostic methods, they are capable of
simultaneously linking morphological and molecular properties of tissues or cells.
Optical spectroscopy, especially autofluorescence (i.e., fluorescence of intrinsic flu-
orophores) and Raman scattering, have been extensively studied for medical diagnosis
in the last 10 years, mainly due to the development of relatively inexpensive and very
efficient light detection devices and the advancements in statistical and computational
methods that allow processing of the increasing amount and complexity of the data
collected.
In the present chapter some of the underlying mechanisms governing the interac-
tion of light with matter are introduced. Emphasis is put on fluorescence, Raman and
surface enhanced Raman scattering (SERS) since these methods constitute the main
optical spectroscopic techniques used in the present work. Chapter 2 provides a brief
introduction to the molecular pathogenesis of the diseases and dysfunctions studied
and general aspects of the diagnostic techniques currently used. The experimental
and statistical tools used for the research presented here are described in Chapter
3 followed by the results myeloproliferative neoplasms (Chapter 4) and, hemoglobin
variants and blood serum (Chapter 5). A brief summary and future directions are
presented Chapter 6.
21.1 Luminescence
The emission of light from excited electron states of any substance is dubbed
luminescence. Depending on the nature of the excited state, luminescence is divided
into two categories: fluorescence and phosphorescence. They differ from each other
in that fluorescence emission occurs from a singlet excited state, whereas phospho-
rescence emission occurs from a triplet excited state.
Luminescence is preceded by the absorption of photons by atoms or molecules,
and it is only one way in which the excited electrons can relax to the ground state.
An atom or a molecule can absorb a photon with energy that is equal to the energy
necessary to take the atom or the molecule to the next excited state (∆E).
Due to line-width broadening, ∆E is not a single value but a distribution of energy
values whose shape depends upon the following factors: 1) The uncertainty princi-
ple, otherwise known as natural broadening, which depends on the excited state
lifetime; 2) Doppler broadening where the velocity distribution of the atoms or
molecules results in a distribution of absorption frequencies that follows the Maxwell’s
statistical distribution function; 3) Collision broadening in which the atomic or
molecular energy levels are shifted due to interparticle collisions; and 4) power
broadening, which takes place above a certain excitation intensity threshold where
nonlinear optical phenomena start to occur.
In addition to the line-width broadening, transitions from the ground state to the
excited state can take place from one of the vibrational sublevels in the ground state
to one of those associated with the excited state. As a result photons with a broad
spectrum of energies can be absorbed. Similarly, the luminescence spectrum can also
be symmetrically broadened.
There are many competing processes by which the excited atom or molecule can
return to the ground state. Fluorescence competes with phosphorescence as well as
with other relaxation mechanisms of relaxation that do not involve the emission of
photons, namely nonradiative transitions:
• Internal conversion by which the atom or the molecule is able to relax by
converting the electronic energy into vibrational and rotational energy.
3• Energy transfer by which the atom or the molecule transfers the excess energy
to another by either collision or resonance transfer energy (RET)
• Intersystem crossing by which the excited electron’s spin flips and the molecule
goes from the singlet to the triplet manifold, thus further internal conversion or
the emission of a photon (phosphorescence) may proceed.
The fate of an excited state is summarized in a Jablonski-type diagram as schemati-
cally shown in Figure 1.1.
The intensity at which the substance will fluoresce is determined by the competi-
tion among the processes describe above, and consequently the quantum yield can be






where Kf us the dissipation rate of fluorescence and Ki are the dissipation rates of
various processes.
1.2 Raman scattering
Scattering is one of the phenomena by which light and matter interact. Elastic
scattering (i.e., Rayleigh and Mie scattering) is the case when the scattered photons
have the same energy as the incoming ones. In contrast, Raman scattering is inelastic
light scattering in which the impinging photons lose (or gain) energy to (or from) the
scattering medium. Unlike absorption, scattering does not require the energy of the
incident photon, Ein, to be equal to the energy difference between electronic energy
levels ∆E. However when Ein becomes closer to ∆E, the Raman cross-section is
enhanced, a phenomenon known as resonant Raman scattering (RRS).
Stokes raman scattering refers to the case in which the photon loses energy
to the scattering material, whereas anti-Stokes Raman scattering is the case in
which the photon gains energy from the scattering medium. The amount of energy
4Figure 1.1: Jablonski diagram of the possible transitions following photon absorption
of a photon. S=Singlet state, T=Triplet State, Abs=Absorption, F= Fluorescence,
Ph=Phosphorescence, VR= Vibrational Relaxation, IC= Internal Conversion and
ISC= Intersystem crossing to the triplet manifold.
lost (or gained) is equal to the the energy difference between two vibrational states
of the molecules in the medium.
The origin of the scattered light is the oscillating electric and magnetic moments
induced in a molecule by the electromagnetic field of the incident light. In the classical
theory framework, the induced electric dipole of a molecule in the presence of an
external electric field can be written as a converging series:
~p = ~p(1) + ~p(2) + ~p(3) + · · · (1.2)
The relation between the first three induced dipole moments and ~E, the field of
the incident monochromatic plane wave, is given by:








γ¯ ~E ~E ~E (1.5)
where α¯, β¯ and γ¯ are the second rank (2× 2) polarizability tensor, third rank (3× 3)
hyperpolarizability tensor and the fourth rank (4 × 4) second hyperpolarizability
tensor, respectively.
The Raman scattering frequency is obtained from the first induced dipole moment
~p(1). The polarizability tensor α¯ is a function of the nuclear coordinates. Nuclei
vibrate about their equilibrium positions, and such vibrations can be expressed in
terms of normal coordinates ~q, and each component of the polarizability tensor αij
can be expressed as an expansion around the equilibrium position [1]:


















qnqm + · · · (1.6)
Assuming both mechanical1 and electrical 2 harmonicity, eq. 1.6 takes the form:
αij = (αij)0 + (α
′
ij)nqn0 cos(ωnt+ δn) (1.7)









The incident monochromatic plane wave frequency dependence is given by:
~E = ~E0 cos(ω1t) (1.8)
and the first induced dipole moment is then expressed as:
~p(1) = α¯0 ~E0 cos(ω1t) + α¯
′
nqn0 ~E0 cos(ωnt+ δn) cos(ω1t) (1.9)
1Vibrations are described by the simple harmonic oscillator.
2Only the first two terms of the expansion of the polarizability are considered.
6Using the trigonometric identity cosA cosB = 1
2
(cos(A + B) + cos(A − B)), eq.
1.9, can be rewritten in the following form:
~p(1) = ~p(1)(ω1) + ~p
(1)(ωn + ω1) + ~p
(1)(ωn − ω1) (1.10)
In eq. 1.10, the first term ~p(1)(ω1) correspond to Rayleigh scattering and the other
two terms, ~p(1)(ωn+ω1) and ~p
(1)(ωn−ω1) correspond to anti-Stokes and Stokes Raman
scattering, respectively.
The intensities of the Rayleigh (eq. 1.11) and Stokes and anti-Stokes Raman (eq.
1.12) scattered light correspond to the intensities of electric dipoles at frequencies ω1,
ω − ω1 and ω + ω1, respectively, where ω is the frequency of a molecular vibration.

















In the case of bulk matter, the intensities of the Stokes and anti-Stokes scattered
light are proportional to the average number of molecules at the vibrational ground
and excited states, respectively. In thermal equilibrium the vibrational population
















7where k is the Boltzmann constant, ~ is the reduced Planck constant, T is the
temperature and N is the total number of molecules. From eqs. 1.12, 1.13 and
1.14 it is found that the ratio of anti-Stokes to Stokes Raman scattered light at the
i-th vibration mode is proportional to the ratio of the forth power of the scattered
frequencies and to the ratio of the excited and ground states populations:
IAS
IS
∝ (ω + ω1)
4
(ω − ω1)4 e
− ~ωs
kT (1.15)
The proportionally constant for relation 1.15 is determined by the polarizabil-
ity tensors for Stokes and anti-Stokes Raman scattering, which under nonresonant
conditions are the same thus making relation 1.15 an equation. Consequently, from
the Raman scattering spectrum one can calculate the temperature of the sample
as shown in Figure 1.2, where the temperature of C60 molecules was calculated for
different illumination conditions from the ratio, IAS/IS.
The polarizability tensors α¯0 and α¯Raman carry information about the molecule and
determine whether Rayleigh or Raman scattering are observable, respectively. Since
all molecules are polarizable to some extent, α¯0 always has nonzero components; thus
Rayleigh scattering is observable from all molecules. On the other hand, from eq. 1.9
it is evident that for Raman scattering to be observable, α¯Raman must have a nonzero
gradient (evaluated at the equilibrium position). This condition imposed on α¯Raman
implies that not all vibrational modes are Raman active. Some of the components
of α¯Raman can still be zero. For those modes the derivative of the permanent dipole
moment at the equilibrium position is finite and thus infrared active [1]. If the
molecule is centro-symmetric, there is a complimentary relation between modes that
are Raman-active and those that are IR-active.
Raman scattering spectrum is highly molecular specific, thus allowing identifica-
tion of the active molecules. Also, since Raman scattering intensity is proportional
to the number of molecules, relative concentrations of substances can be measured
in some circumstances. This has enabled Raman scattering to become an important




Figure 1.2: Raman spectra of solid C60 at room temperature and for different laser
power densities. Reprinted with permission from [2]. Copyright 1998, Elsevier.
9The Raman scattering process described above is dubbed spontaneous and is a
linear process. Eq. 1.12 shows that spontaneous Raman scattering has an intensity
that depends linearly with the excitation intensity (i.e., the square of the incoming
electric field). From eq. 1.12 the power of the Stokes process from N active scatterers
may be expressed as:
PS(ωs) = NσI(ω) (1.16)
where σ is the Raman scattering cross section and I(ω) is the intensity of the incident
beam.






making spontaneous Raman scattering an inherently weak process, and for practical
applications, enhancement is necessary. SERS is an enhancement technique where
the probed molecules are close to a metallic nanoparticle. The theory of SERS is
summarized in the following section.
1.3 Surface enhanced Raman spectroscopy
Most of the features observed from the enhancement of Raman scattering near a
metallic nanoparticle can be explained by two effects [4–6]: (i) electromagnetic
enhancement due to the excitation of localized surface plasmons in the metal
structure and (ii) chemical enhancement due to adsorption of molecules onto
the metallic surface.
Electromagnetic enhancement originates from the ability of subwavelength metal-
lic particles to sustain oscillating surface plasmons induced by impinging electromag-
netic waves. The surface plasmons are collective oscillations of the free, or almost free,
electrons on top of the stationary ionic nuclei background. Localized surface plasmons
are not to be confused with surface plasmon polaritons. To disambiguate these two
concepts, a brief explanation of the former is given followed by the explanation of
localized surface plasmons, which are responsible for electromagnetic enhancement of
Raman scattering.
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Surface plasmon polaritons (SPP) are electromagnetic waves propagating along
the flat interface between a dielectric and a conductor. They decay exponentially
in the direction perpendicular to the metal surface. Using Maxwell’s equations and
the continuity of the electric and magnetic fields, one can show that only transverse
magnetic (TM) modes excite SPPs. For TM polarization the dispersion relation of






where β is the propagation constant of the SPP, k0 is the wave vector in the dielectric,
and 1 and 2 are the frequency dependent dielectric constants of the metal and
dielectric, respectively. From eq. 1.17 one can see that the SPP momentum exceeds
the momentum of a photon in the dielectric (k0
1/2
1 ) for every frequency ω. Thus, in
order to excite SPPs, phase matching is required.
In the case of small metallic structures, the high surface curvature leads to non-
propagating excitations of the conducting electrons dubbed localized surface plas-
mons . The surface curvature acts as an effective restoring force that allows reso-
nances and also renders phase matching conditions unnecessary [6]. The main features
of localized surface plasmon resonances (LSPR) can be understood by studying the
case of a subwavelength spherical metallic particle. Assuming that a, the radius of the
particle, is smaller than the wavelength λ0 of the impinging electromagnetic wave,
it is valid to use the electrostatics approach, i.e., solve for Laplace’s equation of a
metallic particle in an uniform electric field (see Figure 1.3). The solution yields the
following electric potentials inside and outside the metallic nanoparticle:
φin = − 2m
+ 2m
E0r cos θ (1.18)







Figure 1.3: Metallic sphere placed in a uniform electric field.
Eq. 1.19 is the superposition of the applied field and the dipole located at the
center of the sphere, and it can be rewritten in terms of the dipole moment
−→
P as:






P = a3 −m
+2m
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From eq. 1.21 it is evident that α exhibits a resonance as → −2m. For a Drude







is the plasma frequency. Taking interband transitions into account




2 − ω2p) + iωγIT
((IT + 3)ω2 − ω2p) + iωγ(IT + 3)
(1.22)
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Eq. 1.22 has a resonance with width ∼ γ(IT +3). If the metal is a poor conductor,
γ is large and the quality of the resonance goes down. Resonance quality is also
reduced for metals whose dielectric properties are highly modified by interband tran-
sitions [5]. Interband contributions are larger in gold than in silver, thus explaining
the larger SERS enhancement observed in silver [5]. Additionally, in the visible range
the real part of (ω) is fairly close to −20 for both gold and silver (see Figure 1.4),
but the imaginary part is higher in gold. This implies that in the visible range the
enhancement factor in silver is larger.
LSPRs lead to the enhancement of the electric field in the vicinity of a metallic
nanostructure as demonstrated for the case of a metallic nanosphere. From eqs. 1.21
and 1.22 the expected dependence of LSPR on the geometry of the particle is not
evident. To gain a little more insight of the LSPR one can solve for the polarizabilities
of an ellipsoid along the principal axis. Eq. 1.23 shows such polarizabilities where
Li is a geometrical factor and
∑
i Li = 1. Notice that for a spheroidal particle (i.e.,
an ellipsoid with two identical principal axis) only two spectrally resolved plasmon
A B
Figure 1.4: The real 1 and imaginary 2 dielectric constants of A: Silver and B:
Gold normalized to 0. Reprinted with permission from [7]. Copyright 1972, American
Physical Society.
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resonances are observed as two plasmon resonances are degenerate.
αi = a1a2a3
(ω)− m
3m + 3Li((ω)− m) (1.23)
The resonance of spheroids along the major axis are red-shifted compared to the
plasmon resonances of a sphere with the same volume. This is a very attractive
property of LSPR as it allows tunability of the resonances by changing the aspect
ratio of the particles.
In the presence of the enhanced electromagnetic field, both the incoming and the




whereG(ω) is the enhancement factor defined asG(ω) = EM
E0
and EM is the magnitude
of the enhanced field close to the metallic nanostructure.
In the case of the metallic sphere from eq. 1.19 the enhanced electric field at a
























Examples of the enhancement factor under resonant conditions for various ge-
ometries are displayed in Figure 1.5. Notice that for the bipiramidal geometry, the




Figure 1.5: The field enhancement factor at the surface plasmon resonance of A: a
gold sphere B: a gold spheroid and C: a gold bipiramid calculated by finite difference
time domain (FDTD) method. Polarization is along the z direction. Reprinted with
permission from [8]. Copyright 2007, American Physical Society.
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due to the increase of induced charge density at the sharper features of the geometry,
known as lighting rod effect.
An LSPR enhances not only Raman but other linear and nonlinear processes. Such
is the case of fluorescence and second harmonic generation. In the case of fluorescence,
the enhancement results as a consequence of the modification of the excitation and the
emission processes alike. In the surroundings of a metallic structure the fluorescent
molecule (i.e., fluorophore) can be excited by the enhanced EM field and the metallic
surface can serve to direct the emission towards the detector as well, thus increasing
the overall detected intensity of the emitted light. Moreover the metallic nanostruc-
ture modifies the relaxation processes of the fluorophore; close proximity to the metal
surface increases the rate of nonradiative process thus quenching fluorescence. For
larger distances, the rate of radiative processes is higher than nonradiative ones due
to modifications of the environment, and therefore fluorescence is enhanced. The
increase of the radiative rate is a consequence of the reduction of the fluorescence
lifetime (Purcell effect) that increases the emission quantum yield [9]. Since the
surface of any material lacks inversion symmetry, which is a necessary condition for
second harmonic generation (SGH), the metallic nanostructures thus emit frequency
doubled light. The enhancement of SGH is a direct consequence of the enhancement
of the excitation and emitted electric field due to localization [6, 10].
An additional mechanism for the emission enhancement is the so called chemical
enhancement. Chemical enhancement encompasses a handfull of observations that
the electromagnetic theory is incapable of explaining. Among them, molecules with
almost identical Raman cross sections have SERS spectra that vary both in intensity
and the amount of shift that Raman peaks display. Such effects are observed in
SERS spectra of CO and N2 [11] and ethane/methane and ethylene/benzene [4].
Additionally, EM theory predicts that the SERS spectrum should be more or less an
enhanced copy of the normal Raman spectrum. In reality, however, forbidden vibra-
tional bands are observed with SERS whereas bands expected to have high intensity
are abscent. Finally there is a disagreement between the predicted enhancement
factor between EM theory (∼ 1011) and the actually observed factor (1014, [12, 13]).
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These observations can be explained by a resonant process due to the adsorption of
the probed molecules onto the metallic nanostructure surface [5].
1.4 Properties of nanoparticles
As described above, the LSPR frequency depends not only on the metal but
also on the size and shape of the particle as well as the dielectric properties of the
surrounding medium [14]. Additionally, interparticle interactions also change the
optical properties, and will be explained in more detail below.
The condition for the LSPR dictates that → −2m; thus the electric properties
of the surrounding media are capable of moving the resonance towards higher or
lower wavelengths. Such changes are reflected in experiments done by Evanoff et
al., where Ag nanoparticles were placed in five different media of different dielectric
constants [15] (see Figure 1.6).
The LSPR also depends on the shape and size of the nanoparticles. An example of
this is shown in Figure 1.7A, where the extinction spectra of spherical, pentagonal and
triangular particles of comparable sizes are shown. Figure 1.7B shows the extinction
spectra for spherical particles with different diameters. As the particles increase in
Figure 1.6: Extinction spectra of silver nanoparticles in solution before (thin line)
and after (thick line) surrounding dielectric medium was changed from A: isopropanol
to teflon, B: water to silica and C: water to titania. Reprinted with permission from




Figure 1.7: Extinction spectra of A: spherical, pentagonal and triangular silver
nanoparticles particles. Reprinted with permission from [16]. Copyright 2002,
American Institute of Physics; and B: spherical silver nanoparticles with 20 different
diameters. Reprinted with permission from [15]. Copyright 2007, Springer.
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diameter, the maximum in the LSPR is red-shifted. The second peak that appears
at ∼ 420nm is attributed to the quadrupole [15].
For many applications, single nanoparticles are not used. Instead metallic aggre-
gates, which have different optical properties, are utilized. In metallic aggregates, the
individual particles couple through dipole-dipole interactions and generate plasmon
modes that cover the a larger protion of the aggregate. Such modes cover a broader
frequency region as shown in Figure 1.8 [14,17,18].
In the last 30 years or so, thanks to the development of technologies to manufacture
nanoparticles in a controlled and reproducible way, many applications in medical
therapeutics, diagnosis and drug delivery have flourished. Some applications, such
as those aimed at cancer therapy and magnetic resonance imaging (MRI) contrast,
have been already approved by the Food and Drug Administrations (FDA) and are
currently in clinical use [19].
1.5 Thermal effects and photochemical processes
Following light absorption, molecules are left in an excited stated that can relax
back to the ground state through radiative and nonradiative processes. The nonra-
diative process proceeds by dissipating the energy from the excited state as heat or
by producing a chemical reaction (i.e., photochemical reactions).
The thermal effects are attributed internal conversion, intercrossing system, and/or
vibrational relaxation (i.e., conversion of energy to vibrational energy). A notorious
thermal effect is carbonization which occurs in organic compounds such as polymers or
biologically relevant molecules like proteins, lipids, polysaccharides and nucleic acids.
Through the heat induced cleavage of bonds and rearrangement, these materials are
converted into amorphous carbon-like structures. Other thermal effects are slow
compared to photochemical process, which can be three to four orders of magnitude
faster.
Photochemical processes include photoaddition, photofragmentation, photooxida-
tion, photohydration, cis-trans isomerization and photorearrangement [20]. Some
examples [20] are the photodymerization of thymine, light induced protein-DNA
crosslinking, rivoflavin photofragmentation, photooxidation of cholesterol, photoiso-
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Figure 1.8: Extinction spectra for aggregates at various aggregation states as shown
by the SEM images. Reprinted with permission from [17]. Copyright 2002, IOP.
20
merization of 11-cis-retinal and the rearrangement of 7-dehydrocholesterol to vitamin
D upon UV radiation. See Figures 1.9 and 1.10.
1.6 Interaction of light with cells and tissue
The interaction of light with biological samples, such as cells and tissue, leads to
fluorescence and light scattering processes as well as photochemical processes. Some
of the molecules that make up biological specimens fluoresce. Such molecules are
called endogenous or intrinsic fluorophores. The absorption and emission spectra of
representative endogenous fluorophores are depicted in Figure 1.11. In the case of
proteins (e.g., collagen and elastin), the fluorescence originates with the aromatic
amino acids tryptophan, tyrosine and phenylalanine; the emission of tryptophan is
particularly sensitive to its surroundings; hence it is used as a reporter of protein
conformational changes [21]. Another important group of endogenous fluorophores
are the metabolism coenzymes called Nicotinamide adenine dinucleotide-Reduced
(NADH) and Flavin adenine dinucleotide (FAD). These coenzymes help cellular
processes by carrying electrons from one reaction to another. Thus they are essential
for cellular metabolism. NADH and FAD exist also in the oxidized NAD+ and
reduced form FADH2, respectively, which are not fluorescent. NADH and FAD
have distinct absorption and emission spectra (Figure 1.12), and the optical redox
ratio, calculated as the ratio of emission intensities of NADH and FAD, serves as a
measurement of metabolism alterations in cells [22].
In a Raman scattering spectrum, each peak corresponds to a vibrational mode
of a molecule. Therefore each molecule has a very specific Raman fingerprint. Some
examples of Raman scattering spectra from biologically relevant compounds are shown
in Figure 1.13. For simple systems, Raman scattering provides a mean of compound
identification and quantification. On the other hand, Raman scattering spectra of
highly complex systems, such as cells and tissues, can be challenging to interpret in
an absolute way. However, pathological changes that lead to molecular and structural
alterations can be reflected in the Raman spectra and allow Raman scattering to be





Figure 1.9: Examples of photochemical process in biomolecules A: Photodymer-
ization of thymine B: photoisomerization of 11-cis-retinal C: Rearrangement of
7-dehydrocholesterol to vitamin D. Reprinted with permission from [20]. Copyright





Figure 1.10: Examples of photochemical process in biomolecules continued D: Light
induced protein-DNA crosslinking E: Rivoflavin photofragmentation F: Photooxida-





Figure 1.11: Spectra of fluorophores present in biological tissue A: Absorption and
B: Emission. Reprinted with permission from [21]. Copyright 2007, Springer.
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Figure 1.12: Absorption and emission of NADH and FAD, coenzymes involved in
cellular metabolism. Reprinted with permission [21]. Copyright 2007, Springer.
Figure 1.13: Raman spectra of pure compounds. A: Blood; B: mucus; C: proteins;
D:collagen and F: calf thymus DNA. Reprinted with permission from [23]. Copyright
2009, Elsevier.
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for a wide range of diseases such as breast cancer [24], lung cancer [25], leukemia [26],
prostate and bladder cancer [27], oral carcinoma [28], atherosclerosis [29], bone [30]
and macular degeneration [31]. The low concentration of molecules within a cell
and the subtle spectral changes make Raman scattering difficult to implement and
suggest SERS may be better suited. In addition, SERS is excellent for single molecule
inspection, serving as an excellent alternative for protein structure studies [32–35].
In addition to optical responses, tissue and cell also undergo photochemical pro-
cesses and thermal effects initiated by light absorption. At the tissue level, such
processes, going from lower to higher temperature thresholds, are coagulation, va-
porization, carbonization and melting. Above 60oC, the tissue becomes necrotic (i.e.,
dead), a process known as coagulation. Vaporization is reached when the water within
the tissue starts to evaporate (that is at 100oC). The damage produced by vaporization
is purely mechanical caused by the expansion of the water. Carbonization occurs
when the tissue reaches over 150oC, and the organic compounds are converted to
carbon. For sufficiently high temperatures tissue can also melt, which is used for
tissue welding [20].
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There are more than 100 distinct types of cancer [1]. Hanahan and Weinberg
suggested in 2000 that all the cancerous genotypes are the manifestation of six essen-
tial alterations in the cell: self-suffiency in cell growth, insensitivity to anti-growth
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis
and tissue invasion and metastasis. Recently it has been suggested that metabolomic
alterations have to be included in that list [2]. In the present chapter, the mechanisms
accountable for these features are described.
2.1.1 Pathogenesis: cancer is a genetic disorder
The way cancer pathogenesis is understood has changed radically since the dis-
covery of oncogenes and tumor suppressor genes (TSG), which are sequences in
the DNA that upon activation and deactivation, respectively, could induce cancerous
transformation. Although simple in concept, activation of a single oncogene is not
enough to induce transformation. Two or more active oncogenes are required, and as
transformation progresses cells acquire more mutations [3]. A transformation based
solely on activation of oncogenes will take longer than what is observed clinically,
as the chance for each mutation to happen is very low. TSGs are genes that help
regulate responses in normal cells aimed to control growth and proliferation, and
cancerous cells appear as if they have lost the normal expression of these genes. Still,
the chances of DNA mutations at the right places are very low, especially taking
into account that each gene has two copies in each cell. Unfortunately, there is an
additional mechanism by which cancerous cells can overcome such ‘problems’. Loss
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of heterozygosity (LOH) is the process by which malignant cells are able to discard
the chromosomal arm that has the intact copy of the TSG and replace it with a copy
of the arm that has the mutated version [3].
The chances of a gene mutation are not only stochastically low, but are further
reduced by the existence of molecular machinery that is capable of detection and
repair of defective DNA. Faulty DNA repair, in turn, accelerates transformation
and seems to be a feature present in a great majority of human cancers [3]. So
far, mechanisms that affect the DNA sequence directly have been described. Unfor-
tunately, additional mechanisms (i.e., epigenetic mechanisms) that assist cancerous
transformation exits, such as the case of DNA methylation, which is an important
mechanism to regulate gene transcription. It results from the addition of a methyl
group to a cytosine ring. The methylation pattern is inherited from parents and it
is maintained by the methylase. The methyl group regulates expression by creating
a physical barrier between the DNA and the transcription machinery, and modifying
histones, thus helping to create large parts of inactive chromatin. Hypermethylation,
the abnormal addition of methyl groups, can lead to the deactivation of TSG whereas
hypomethylation, the abnormal removal of methyl groups, can lead to the activation
of oncogenes [4].
Cancer cells can grow and divide indefinitely, while normal cells only divide for
a finite number of generations. In a normal cell, the telomeres of the chromosome
shorten during each cycle of growth and division. Eventually they become too short to
perform their job of preventing fusions among different chromosomes. At this point
the cell enters the death program and no further division takes place. Cancerous
cells seem to have activated the expression of telomerase, the enzyme that repairs
telomeres. Expression of telomerase is detectable in almost all human cancers [3]. In
many cases, collaborative genetical and epigenetical modifications give cancer cells
the acquired ability to migrate and establish themselves elsewhere in the body. This
process is dubbed invasion and metastasis.
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2.2 Diagnosis
Histopathology is the gold standard for cancer diagnosis. It bases the diagnosis
on structural changes of the tissue. Paraffin embedded sections of the tissue are
stained with hematoxylin and eosin (H&E) and observed under an optical microscope
(See Figure 2.1). The result strongly depends on proper handling of the tissue
sample. Moreover, the sample must undergo appropriate preparation and processing,
which could take up several days [5]. Even if ideal conditions have been met up
to this point, uncertainty in the interpretation of biopsies is an inherent problem
of histopathological diagnosis because i) the sample may have been obtained at a
stage when the cancerous features have not yet been fully developed, ii) treatment
procedures, like irradiation and chemotherapy can change the morphology of the
tissue, iii) mechanical, electrical and thermal stress can alter morphological features
and iv) some malignancies, by nature, differ very little from other malignant, benign
or reactive disorders [5].
In addition to histopathology, cytopathology, the study of the morphology of
individual cells, is often used as a screening technique. Cytopathology has high
sensitivity (i.e., few cancer cases are missed) but has low specificity, meaning that
patients without cancer will undergo additional testing, increasing the overall cost
A B C D
Figure 2.1: H&E stained images of A: Normal squamous tissue, B: abnormal hy-
perplasia, C: carcinoma in situ and D: dysplasia. All images are X200 magnification.
Reprinted with permission from [6]. Copyright 2003, Nature Publishing Group.
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of diagnosis [5]. An important problem in diagnosis is the interobserver variability,
which has been estimated to be as high as 10% [7]. Additionally, discrepancies in the
diagnosis made from histopathology and cytopathology within the same institution
can be as high as 12% [8].
In approximately 10% of all oncology cases, histopathology and cytopathology
are not sufficient to confirm a diagnosis. In such cases, additional, more special-
ized and more expensive tests, like histochemical stains, electron microscopy and
immunochemistry, are used. Flow-cytometry is another important technique used to
identify different cell populations within a sample which is done by labeling cells with
fluorescent labels that bind to specific membrane markers. Finally, techniques aimed
at measuring gene expression and DNA mutations are also used, although they are
not widely available. Examples of such techniques are polymerase chain reaction and
in situ hybridization and fluorescent in situ hybridization [5].
All things considered, novel diagnostic tools are a necessity for a faster, cheaper
and more accurate diagnosis. Any new technique will have to fulfil many requirements.
i)The new processes should be simple to implement, with mandatory feasibility for
automatization, which in turn will lead to faster diagnosis and lower interobserver
variability, ii) the new techniques should be label/reagent free, which will help reduce
costs, and importantly, iii) the new methods should have not only high sensitivity but
also high specificity, thus reducing the necessity for additional tests. Simultaneously
fulfilling these three requirements is the challenge of the new generation of diagnostic
tools.
2.3 Cellular metabolism in normal and
neoplastic cells
Cells obtain the energy necessary for their survival and proliferation via two
mechanisms, Glycolysis and the Krebs cycle. Under normal conditions (i.e., normal
oxygen tension), cells convert one molecule of glucose into 36 adenosine triphosphate 1
1Adenosine triphosphate is a nucleotide with three phosphate groups. Energy is stored
in ATP molecules in the phosphate bond which can be released by the hydrolysis of ATP
into ADP (Adenosine diphosphate).
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(ATP) molecules through the process called the Krebs cycle or the tricarboxylic acid
(TCA) cycle. In conditions with limited oxygen (hypoxic conditions), cells switch
their metabolism mechanism to anaerobic glycolysis which results in the increased
production of lactic acid.
Some cancer cells show a steep increase in the consumption of glucose and produce
lactic acid instead of metabolizing glucose through the TCA cycle, even in the
presence of sufficient oxygen. This phenomenon is termed aerobic glycolysis or
Warburg effect, after Otto Warburg who received the Nobel prize in 1931 for his
work on cellular metabolism.
In this section a brief introduction to glycolysis, the tricarboxylic acid cycle and
the Warburg effect are presented to give context to the work developed in Chapter 4.
2.3.1 Glycolysis
Glycolysis is the metabolic pathway in which glucose is broken and oxidized to
form pyruvate. The main role of glycolysis is the formation of ATP and nicotinamide
adenine dinucleotide (NAD), although glycolysis also provides biosynthetic precursors
for the synthesis of fatty acids, amino acids and nucleotides.
The glycolytic pathway cleaves and oxidizes 1 molecule of glucose to 2 molecules
of each pyruvate and ATP, and reduces 2 molecules of NAD in a 10 step process
summarized in Figure 2.2. Each step involves an enzyme that catalyzes the reaction.
Few of these steps require energy to proceed but there is at the end a net production of
ATP molecules. Pyruvate, the other molecular product of glycolysis, is the starting
point for the TCA cycle, as described in the next section. NAD is an important
coenzyme involved in reduction-oxidation (REDOX) reactions as it serves as an
electron carrier. During glycolysis, molecules of NAD are reduced to NADH, a fact
that as explained below, can be used to spectroscopically measure alterations to
cellular metabolism.
2.3.2 Tricarboxylic acid cycle
For the TCA cycle to take place, a preparatory step is required: Pyruvate needs

























































































































































































































































































































































































































































Unlike glycolysis that takes place in the cytosol, pyruvate decarboxylation and the
TCA cycle take place in the mitochondria. As shown in Figure 2.3, Acetyl-Co is
the true starting point of the TCA cycle, which is converted into citrate, and at the
end of the cycle, the oxaloacetate is recovered and the cycle starts again. The TCA
cycle takes electrons from Acetyl-Co and uses them to form NADH and to reduce
Flavin Adenosine (FAD) to form FADH2. Oxygen is necessary at the end of the
cycle to regenerate NAD and FAD. The net products of the TCA cycle are two ATP
molecules. So, where are the additional 34 ATP molecules coming from? The answer
is oxidative phosphorylation.
Oxidative phosphorylation is the final part of the aerobic metabolism, and it
uses the electrons in NADH and FADH2 to generate a proton gradient across the
mitochondrial membrane which then activates ATP Synthase, the protein complex
that synthesizes ATP. Redox reactions are done by four protein complexes (including
ATP Synthase) located in the inner membrane of the mitochondria in the presence of
oxygen. Oxygen is the last electron acceptor and is essential for the regeneration
of NAD and FAD. From the oxidative phosphorylation between 30 and 36 ATP
molecules are produced.
2.3.3 Hypoxia and Warburg effect
Warburg effect, or aerobic glycolysis, is the name given to the observed effect
in which cancerous cells display a higher glucose uptake and a higher lactic acid
production even under normal oxygen (normoxic) conditions. For reasons that will
be described, cancerous cells do not metabolize glucose through the TCA cycle but
instead they do so by just glycolysis, which in turn increases the production of
pyruvate. Glycolysis involves the reduction of NAD to NAHD. In a normal cell
under sufficient oxygen conditions pyruvate will enter the TCA cycle. However, when
there is not enough oxygen available to proceed with the oxidative phosphorylation
and therefore oxidize NADH back to NAD, glycolysis is not possible due to a shortage
in NAD. Instead, pyruvate can be used as a substrate for the oxidation of NADH in






































































































































































Figure 2.3: Tricarboxylic acid cycle. Reprinted under the Creative Commons
Attribution-Share Alike 3.0 Unported license from [10].
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lactic acid.
One of the ways that normal cells respond to hypoxia is through hypoxia inducible
factor 1 (HIF-1). HIF-1 is a transcription factor2 that in the presence of oxygen, gets
ubiquitylated and thus tagged for proteasome degradation. Under hypoxic condi-
tions HIF-1 activates the expression of genes involved in angiogenesis, metabolism,
cell proliferation, among others [11–13] (See Figure 2.4). In cancerous cells, many
mutations have been identified that lead to increased HIF-1 activity [13,14], which in
turn increases glucose uptake and pyruvate conversion to lactate as well as reduces
mitochondrial activity and mass [14–16].
Several HIF-1 independent mutations have been implicated in the Warburg effect
[16]. Such is the case of the AKT gene which, in turn, also promotes an increase
in glucose uptake and aerobic glycolysis. Myc genes code for transcription factors
that regulate growth and cell cycle entry [3] and are activated in a broad range of
cancers. Myc genes have been associated with both activation of anaerobic glycolysis
and increased mitochondrial activity. Other genes involved in Warburg effect are the
succinate dehydrogenase (SDH) and fumarate hydratase (FH) [16].
Metabolic transformation is important for cancer cells as it not only provides
enough energy, but it provides many of the building blocks necessary for cell prolif-
eration. Additionally, aerobic glycolysis has been linked to cellular immortalization
and antiapoptotic effects [16].
2.4 Myeloproliferative neoplasms
Myeloproliferative neoplasms (MPNs) belong to a family of diseases that originate
in a somatic mutation3 in a self-renewing hematopoietic stem cell. MPNs include four
main diseases: chronic myelogenous leukemia (CML), polycythemia vera (PV), essen-
tial thrombocythemia (ET), and primary myelofibrosis (PMF). CML is characterized
2A protein that can increase (upregulate) or suppress (downregulate) the expression of
genes.
3A somatic mutation is an acquired mutation as opposed to a germline mutation, which
is an inherited mutation.
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PDK1
Figure 2.4: Genes that are involved in many processes are transcriptionally activated
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by the BCL-BCR fusion gene (i.e., Philadelphia chromosomal abnormality). PV, ET
and PMF are Philadelphia chromosome negative The major features of MPNs are
increased production of red blood cells in PV, high platelet count in ET and bone
marrow fibrosis in PMF [17–19]; all three share common characteristics such as bone
marrow hypercellularity, predisposition to thrombosis and hemorrhage and increased
risk of transformation to acute myeloid leukemia [18].
Nonphiladelphia MPNs are thought to originate in the transformation of a hemato-
poietic stem cell, but their molecular pathogenesis has yet to be completely elucidated
[18,19]. Nonetheless, key molecular features of MPNs have been discovered in recent
years and are briefly outlined in the following section.
2.4.1 Pathogenesis
In 2005 the valine to phenylalanine substitution at the 617 residue of the tyrosine
kinase gene that encodes for JAK2 was reported by several groups [18, 20–23]. The
JAK2 V617F mutation is not in the germline, but it is rather acquired, and it
has been shown to be present in 90-95% of PV patients as well as in 50-60% of
ET and PMF patients [17, 19]. This mutation causes cytokine4-independent ac-
tivation of JAK-STAT, PI3K, and AKT pathways and mitogen-activated protein
kinase (MAPK) and extracellular signal-regulated kinase (ERK), all of which are
linked to the erythropoietin receptor (EPOR) that has an important role in cellular
auto-inhibition, in other words, apoptosis, proliferation and differentiation [19]. The
mutation is at a motif that renders EPOR ubiquitously active, even in the absence of
erythropoietin, the cytokine produced in the kidney and liver responsible for EPOR
activation under normal conditions (see Figure 2.5). The JAK2 V617F mutation
explains the formation of erythropoietin independent erythroid colonies (i.e., bone
marrow progenitor cells colonies), a hallmark of polycythemia vera , but is not
necessary as demonstrated by the formation of colonies in PV patients without the
JAK2 V617F mutation [24].
4Small proteins used for intercellular signalling. Citokines trigger cellular responses by
binding to receptors located at the surface of the cells.
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Figure 2.5: Under normal conditions, EPOR is inactive in the absence of erythropoi-
etin. The binding of erythropoietin induces conformational changes to EPOR, causing
the phosphorylation of JAK2 and thus the activation of signalling pathways. In cells
with the V617F mutation the binding of erythropoietin is outwitted. Reprinted with
permission from [19]. Copyright 2006, Massachusetts Medical Society.
Although the discovery of the JAK2 V617F mutation helps explain many of the
key features of PV, there is strong evidence that JAK2 V617F mutation is not the
initiating mutation. For example, it is known from in vitro transfection experiments
that wild JAK2 is dominant over JAK2 V617F, and it is also known that most
PV patients are heterozygous for the JAK2 V617F mutation. Additionally, in some
women, the number of clonal granulocytes outnumber those of JAK2 V617F positive
granulocytes [19]. Finally, the identification of a patient whose complete population
of granulocytes showed the deletion of chromosome 20q but only 7% JAK2 mutant
allele frequency [24]. All suggesting that the JAK2 V617F mutation is not enough
to produce the polycythemia vera phenotype.
Recently it has been found that TET2 (TET oncogene family 2) and CBL mu-
tations are involved in the pathogenesis of MPNs [25, 26], but there is evidence that
neither TET2 [27] nor CBL [26] are disease-initiating mutations.
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2.4.2 Diagnosis
The World Health Organization (WHO) classifies ET, PV, PMF, CML and the less
frequent chronic neutrophilic leukemia, chronic eosinophilic leukemia/hypereosinophilic
syndrome, systemic mastocytosis, and unclassifiable MPD as Myeloproliferative Neo-
plasms. As describe above, ET, PV and PMF share a lot in common, and clinically,
they mimic each other and some other malignant and nonmalignant disorders. Al-
though the JAK2 V617F mutation was a major advance in the diagnostics of MPNs,
it is not specific, meaning it cannot be used to distinguish between one MPN from
another. On the other hand, the absence of the JAK2 V617F mutation has little
diagnostic value in ET and PMF, since only about 50% of patients will have the
mutation [28], and it does not exclude PV. Many tests are used for the diagnosis of
MPN to differentiate among them and to assure diagnosis in the case of JAK2 V617F
negative result.
The differential diagnosis of PV usually starts when an increased red cell mass
(RCM) is observed. Increased RCM can be due to several reasons factors: reactive
erythrocytosis, drugs, pulmonary disease, high altitude, etc. It is not straightforward
but absolutely necessary to rule out those situations. Measurements of hematocrit5
and hemoglobin levels, although routinely done, do not always allow distinction
among MPNs. Table 2.1 summarizes additional tests used for the differential diagnosis
of PV.
PMF is characterized by bone marrow fibrosis and hypercellularity. Its diag-
nosis relies on the right identification of morphologically atypical megakaryocytes,
megakaryocytes proliferation and reticulin and/or collagen fibrosis.
Essential thrombocythemia is characterized by an elevated platelet count (i.e.,
thrombocytosis). Thrombocytosis can be caused by a number of reasons: infection,
renal disorders, blood loss, tissue damage, chronic inflammation, among others [29].
The first step is to exclude the possibility of reactive thrombocytosis due to the
reasons mentioned. The second step is to distinguish ET from any other myeloid
disorder, including CML. At this point, diagnosis of ET becomes challenging as one
5Percentage of blood volume occupied by red blood cells.
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Table 2.1: Additional laboratory tests used in the differential diagnosis of poly-
cythemia vera [29].
Test Technique Description




Cell Colonies EEC is a feature of PV, but it
is not standardized, not available
clinically and negative test does
not exclude PV [29].
Bone marrow biopsy Morphology Will not distinguish PV from
PMF or ET.
Splenic enlargement CT or
ultrasound
of the major criteria for ET diagnosis is that it does meet the criteria for CML, PV or
PMF, i.e., ET is diagnosed by exclusion. Table 2.2 summarizes the WHO diagnostic
criteria for myeloproliferative neoplasms reported in 2008 [28].
2.5 Hemoglobinopathies
Hemoglobinopathies are a group of disorders that affect red blood cells with
abnormal hemoglobin (Hb). They can be divided into expression abnormalities, called
Thalassemias, and structural disorders. Structural disorders are the result of aberrant
hemoglobin molecules, i.e., hemoglobin variants. There are 1118 hemoglobin variants
identified [30]; they are due to a point mutation in a globin gene which produces a
molecule of hemoglobin that has a single amino acid substitution. They receive the
name from where they were discovered, although the first ones were given letters from
the alphabet. The most severe symptomatic hemoglobinopathies are the homozygous
ones; heterozygous ones, also refered to as traits, tend to be milder or asymptomatic,
but some have moderate clinical implications, especially traits of Hb S, the hemoglobin
variant associated with sickle cell disease. Table 2.3 lists some relevant Hb variants.
For a full updated list see [30].
Many of these variants do not have relevant clinical implications, but some like






















































































































































































































































































































































































































































































































































































































































































































































Clinical Features Diagnostic Challenges
S Sickle cell disease None
C Splenic enlargement, mild
hemolytic anemia
None
E Growth retardation, mongoloid
faces,moderate splenomegaly,iron
overload and mild hemolytic
anemia
Hard to differentiate form Hb O
D Asymptomatic when
heterozygous
Hard to differentiate form Hb G
A2 Elevated in people with
β-thalassemia





Hard to differentiate form Hb E
G Asymptomatic when
heterozygous
Hard to differentiate form Hb D
Lepore Asymptomatic Eludes both electrophoretic and
chromatographic methods
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cause substantial overestimation of HbA1c, the important marker for diabetes mellitus
[31]. Hb variants are commonly identified using electrophoretic or chromatographic
techniques. Electrophoresis, at alkaline or acidic pH, is able to resolve common
variant such as S, F, A and C but fails to differentiate E from O and D from G.
Another electrophoretic technique is Isoelectric Focusing, which despite having better
resolution, does not have quantitative capabilities and is very labor intensive [32].
On the other hand, high performance liquid chromatography (HPLC) provides a fast
diagnosis but lacks resolution to differentiate common variants such as E and Lepore
from A2 and D from G. Neither electrophoretic nor HPLC has enough sensitivity to
detect Hb at low concentrations [32].
Cation exchange HPLC has a better resolution than normal HPLC but suffers
from a disadvantage shared with electrophoretic techniques: Since the principle of
separation is based on differences in affinity and charge distribution, variants that
are neutral elude this methods [31]. Mass spectroscopy (MS) has been used for Hb
variant diagnosis as well, but still suffers from some important drawbacks: Due to low
mass resolution MS is unable to differentiate among variants with few mass differences
such as C, D, and E. Moreover, MS is a qualitative technique, so quantification of
important Hb fractions like HbA1c and HbA2 is not possible [31].
2.6 References
[1] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell 100, 57–70
(2000).
[2] R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell
metabolism,” Nat Rev Cancer 11, 85–95 (2011).
[3] J. Mendelsohn, The Molecular Basis of Cancer (Saunders/Elsevier, Philadelphia,
PA, 2008).
[4] P. M. Das and R. Singal, “DNA Methylation and Cancer,” J Clin Oncol 22,
4632–4642 (2004).
[5] R. Lenhard, R. Osteen, T. Gansler, and A. C. Society, Clinical Oncology (Amer-
ican Cancer Society, Atlanta, GA, 2001).
[6] P. Chatrath, I. S. Scott, L. S. Morris, R. J. Davies, S. M. Rushbrook, K. Bird,
S. L. Vowler, J. W. Grant, I. T. Saeed, D. Howard, R. A. Laskey, and N. Coleman,
46
“Aberrant expression of minichromosome maintenance protein-2 and Ki67 in
laryngeal squamous epithelial lesions,” Br J Cancer 89, 1048–1054 (2003).
[7] M. Markman, “Diagnostic pathology: Challenges and increasing complexity,”
Oncology 79, 159–160 (2010).
[8] S. S. Raab and D. M. Grzybicki, “Quality in cancer diagnosis,” CA Cancer J
Clin 60, 139–165 (2010).
[9] YassineMrabet, “Glycolysis.svg,” (Access July 22 2011), http://commons.
wikimedia.org/wiki/File:Glycolysis.svg.
[10] wadester16, “Citric acid cycle with aconitate 2.svg,” (Access July 22 2011),
http://commons.wikimedia.org/wiki/File:Citric_acid_cycle_with_
aconitate_2.svg.
[11] G. L. Semenza, “Signal transduction to hypoxia-inducible factor 1,” Biochem
Pharmacol 64, 993–998 (2002).
[12] A. L. Harris, “Hypoxia - A key regulatory factor in tumour growth,” Nat Rev
Cancer 2, 38–47 (2002).
[13] G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nat Rev Cancer 3, 721–732
(2003).
[14] G. L. Semenza, “Regulation of cancer cell metabolism by hypoxia-inducible factor
1,” Sem Cancer Biol 19, 12–16 (2009).
[15] G. L. Semenza, L. A. Shimoda, and N. R. Prabhakar, “Regulation of gene
expression by HIF-1,” (2006), Vol. 272, pp. 2–8.
[16] J. Kim and C. Dang, “Cancer’s molecular sweet tooth and the Warburg effect,”
Cancer Res 66, 8927–8930 (2006).
[17] A. M. Vannucchi and P. Guglielmelli, “Molecular pathophysiology of
Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mu-
tations,” Haematologica 93, 972–6 (2008).
[18] E. J. Baxter, L. M. Scott, and P. J. Campbell, “Acquired mutation of the tyrosine
kinase JAK2 in human myeloproliferative disorders,” Lancet 365, 1054–1061
(2005).
[19] P. J. Campbell and A. R. Green, “The myeloproliferative disorders,” New Engl
J Med 355, 2452–2466 (2006).
[20] C. James, V. Ugo, J. P. Le Coue´dic, J. Staerk, F. Delhommeau, C. Lacout,
L. Garon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, J. L. Villeval, S. N.
Constantinescu, N. Casadevall, and W. Vainchenker, “A unique clonal JAK2
mutation leading to constitutive signalling causes polycythaemia vera,” Nature
434, 1144–1148 (2005).
47
[21] R. Kralovics, F. Passamonti, A. S. Buser, S. S. Teo, R. Tiedt, J. R. Passweg,
A. Tichelli, M. Cazzola, and R. C. Skoda, “A gain-of-function mutation of JAK2
in myeloproliferative disorders,” New Engl J Med 352, 1779–1790 (2005).
[22] R. L. Levine, M. Wadleigh, J. Cools, B. L. Ebert, G. Wernig, B. J. P. Huntly,
T. J. Boggon, I. Wlodarska, J. J. Clark, S. Moore, J. Adelsperger, S. Koo, J. C.
Lee, S. Gabriel, T. Mercher, A. D’Andrea, S. Frhling, K. Dhner, P. Marynen,
P. Vandenberghe, R. A. Mesa, A. Tefferi, J. D. Griffin, M. J. Eck, W. R. Sellers,
M. Meyerson, T. R. Golub, S. J. Lee, and D. G. Gilliland, “Activating mutation
in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia,
and myeloid metaplasia with myelofibrosis,” Cancer Cell 7, 387–397 (2005).
[23] R. Zhao, S. Xing, Z. Li, X. Fu, Q. Li, S. B. Krantz, and Z. J. Zhao, “Identification
of an acquired JAK2 mutation in polycythemia vera,” J Biol Chem 280, 22 788–
22 792 (2005).
[24] G. Chen and J. T. Prchal, “Polycythemia vera and its molecular basis: An
update,” Best Pract Res Clin Haematol 19, 387–397 (2006).
[25] F. Delhommeau, S. Dupont, V. Della Valle, C. James, S. Trannoy, A. Masse´,
O. Kosmider, J. P. Le Couedic, F. Robert, A. Alberdi, Y. Le´cluse, I. Plo, F. J.
Dreyfus, C. Marzac, N. Casadevall, C. Lacombe, S. P. Romana, P. Dessen,
J. Soulier, F. Viguie´, M. Fontenay, W. Vainchenker, and O. A. Bernard, “Muta-
tion in TET2 in myeloid cancers,” New Engl J Med 360, 2289–2301 (2009).
[26] F. H. Grand, C. E. Hidalgo-Curtis, T. Ernst, K. Zoi, C. Zoi, C. McGuire, S. Kreil,
A. Jones, J. Score, G. Metzgeroth, D. Oscier, A. Hall, C. Brandts, H. Serve,
A. Reiter, A. J. Chase, and N. C. P. Cross, “Frequent CBL mutations associated
with 11q acquired uniparental disomy in myeloproliferative neoplasms,” Blood
113, 6182–6192 (2009).
[27] S. Swierczek, D. Yoon, C. Bellanne-Chantelot, S. Kim, C. Saint-Martin, F. Del-
hommeau, A. Najman, and J. Prchal, “Extent of hematopoietic involvement
by TET2 mutations in JAK2V617F polycythemia vera,” Haematologica 96,
775–778 (2011).
[28] A. Tefferi and J. W. Vardiman, “Classification and diagnosis of myeloproliferative
neoplasms: The 2008 World Health Organization criteria and point-of-care
diagnostic algorithms,” Leukemia 22, 14–22 (2008).
[29] J. V. Melo and J. M. Goldman, Hematologic Malignancies Myeloproliferative
Disorders (Springer, Berlin, 2007).
[30] G. Patrinos, B. Giardine, C. Riemer, W. Miller, D. Chui, N. Anagnou, H. Wajc-
man, and R. Hardison, HbVar , Improvements in the HbVar database of human
hemoglobin variants and thalassemia mutations for population and sequence vari-
ation studies, http://globin.cse.psu.edu/hbvar/menu.html, acessed July 24
2011.
48
[31] P. Kleinert, M. Schmid, K. Zurbriggen, O. Speer, M. Schmugge, B. Roschitzki,
S. S. Durka, U. Leopold, T. Kuster, C. W. Heizmann, H. Frischknecht, and
H. Troxler, “Mass spectrometry: A tool for enhanced detection of hemoglobin
variants,” Clin Chem 54, 69–76 (2008).
[32] C. Ou and C. Rognerud, “Diagnosis of hemoglobinopathies: Electrophoresis vs.




3.1.1 Confocal micro-Raman spectroscopy
Confocal microscopy is a technique that was developed to acquire images and
spectroscopic information with high spatial resolution along the lateral1 and the axial2
directions. The resolution is, in principle, only diffraction limited. The basic idea
of confocal microscopy is that the illumination and the detection beam paths have
the same focal plane. In general, this condition is achieved by 2 pinholes placed at
equal distances from the sample. The main advantage of confocal microscopy is the
improved axial resolution as compared to wide field microscopy. Figure 3.1 depicts
the principle of the setup of a confocal microscope; the pinhole on the detection
path selects only the light emitted from the focal plane. Although resolution can
be improved by the confocal configuration, care must be taken when selecting the
pinhole diameter. If it is too small, it can substantially reduce the amount of light
that reaches the detector. The detection pinhole ultimately provides an improvement
in the axial resolution, and therefore, in cases where high axial resolution is not
required, one can increase the pinhole’s diameter, thus collecting more photons and
reducing the intrinsic noise.
The equipment used for confocal imaging and microspectroscopy was the WITec
alpha300 microscopy system (WITec, GmbH, Ulm, Germany). It is a modular
microscope system that has a photon counting photomultiplier tube (PMT) and a
spectrometer coupled to a charge couple device (CCD) camera, which in turn, allows
1Parallel to focus plane.
2Perpendicular to focus plane.
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Figure 3.1: Principle setup for confocal microscopy. Modified from [1].
both confocal imaging and confocal raman microspectroscopy (See Figure 3.2). The
illumination and detection pinholes are replaced by optical fibers that couple the
laser to the upright microscope and the microscope to the spectrometer or the PMT.
The equipment is also capable of scanning near field optical microscopy (SNOM) and
atomic force microscopy (AFM). Neither of these will be discussed here.
In the actual configuration, light from a 488 nm Argon laser was focused onto
the sample using a microscope objective. A 488 nm ‘notch filter’ was used to reject
the elastic scattering, and unless otherwise specified, a 600 grooves/mm (500 nm
blaze wavelength) diffraction grating was used to disperse the collected emission and
obtain spectra in the 500 to 4500 cm−1 range using a CCD, operating at −60oC
(Andor Technology, Belfast, Ireland). Unless otherwise specified, measurements were
done under atmospheric conditions. Data were acquired and preprocessed using the
WITec control software. Postprocessing was done with Matlab (The MathWorks, Inc.
Natick, MA).
The microscope is also equipped with a piezoelectrically driven 3 axis translation
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Figure 3.2: Experimental setup for confocal micro-Raman spectroscopy
stage that allows automatic scanning of the sample. The maximum scan range is
100µm parallel and 20µm perpendicular to the focal plane.
3.1.2 Silver nanoparticles substrates by Tollens reaction
The Tollens reaction is the deposition of semicontinuous silver films onto glass
through the reduction of silver nitrate by an aldehyde. The first use of the Tollens
reaction for the preparation of SERS active substrates was reported by Ni and Cotton
in 1986 [2]. Since then, many of their properties have been elucidated. For example,
it is known that silver aggregates produced by Tollens reaction organize in a fractal
fashion making them attractive candidates for single molecule SERS [3].
One of the most appealing characteristics of substrates made by the Tollens
reactions is the ease of preparation. The following protocol is based on published
work by Wang et al. [3]. Stock solutions of 0.1 M silver nitrate (AgNO3) and 0.8
M potassium hydroxide (KOH) in distilled water were prepared. A fresh solution
of 0.5 M D-Glucose in distilled water was prepared for every batch. The AgNO3,
KOH, D-Glucose and ammonium hydroxide were analytical grade (Sigma-Aldrich,
St. Louis, MO, USA).
For a final reaction volume Vf , Vf/3 of the 0.1 M AgNO3 was prepared. While
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stirring, the ammonium hydroxide was added one drop at a time to the AgNO3 until
a brown precipitate formed. The ammonium hydroxide was continually added until
the solution was clear. The volume was adjusted to Vf/3. Then, Vf/6 of 0.8 KOH was
added to the AgNO3 solution forming a brown precipitate. Ammonium hydroxide
was added dropwise until the solution became clear again. The glass substrates were
soaked for 10 seconds in the former solution. Note: Glass was previously cleaned
in organic solvents like ethanol and acetone to avoid carbon species contaminations.
Vf/2 of the 0.5M glucose solution was mixed in the AgNO3 solution prepared above.
The glass stood in the final solution for 2 minutes. The size and separation of the silver
nanoparticles will depend upon the time allowed for reaction [3]. The substrates were
rinsed several times with warm and cold distilled water and blown dry using nitrogen
or argon gas.
A scanning electron microscopy (SEM) image of a typical substrate with a reaction
time of 2 minutes is shown in Figure 3.3A. An important feature of this type of
substrates is self-similarity which has been characterized by the power law relationship
between the area root mean square (RMS) of the silver nanoparticles and SEM
imaging area of dimension r × r as shown by:
ARMS(r) = kr
D (3.1)
where D is the fractal dimension, and k is a constant related to the density of the
fractal (i.e., Lacunarity) [4]. Figure 3.3B shows a loglog plot of ARMS versus r, which
demonstrates the self-similarity. Processing of the SEM images was done using the
image processing software ImageJ [5]. Self-similarity is not a necessary nor a sufficient
condition for electromagnetic enhancement although it often results in strong local-
ization of surface plasmons. As a consequence of localization, self-similar substrates,




Figure 3.3: Tollens substrates characterization. A: SEM image of Tollens substrate
with 120 seconds reaction. Scale bar is 100nm B B: Self-similarity behavior of the
silver nanoparticles and aggregates result of the Tollens reaction.
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3.1.3 Cell fraction separation by gradient media
Histopaque 1077 is a solution containing polysucrose and sodium diatrizoate,
adjusted to a density of 1.077 g/mL that allows the isolation of granulocytes, platelets
and mononuclear cell fractions by centrifugation. During the procedure, erythrocytes
from anticoagulated blood are aggregated by polysucrose and rapidly sediment while
granulocytes become slightly hypertonic, which increases their sedimentation rate,
resulting in pelleting at the bottom of the centrifuge tube. Lymphocytes and other
mononuclear cells remain at the plasma/Histopaque interface [7] (see Figure 3.4).
The reagents and procedure used are as follows:
Reagents
• 10X Lysis Buffer: The following is the recipe for a 10X stock solution of lysis
buffer. This buffer has been formulated for erythrocytes lysis while having mini-
mum effect on leukocytes. Mix all the ingredients listed below and adjust volume to
100ml with autoclaved distilled water. Filter solution. Store at room temperature.
– 8.29grams NH4CL.
– 0.79grams NH4HCO3.
– 2ml 0.5M Ethylenediaminetetraacetic acid (EDTA) pH 8.0.
Figure 3.4: Layers form in tube after centrifugation of anticoagulated blood with
histopaque 1077.
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• Phosphate buffered saline (PBS).
• Histopaque 1077(Sigma-Aldrich, St. Louis, MO, USA).
Procedure
1. Draw 10mL of peripheral blood by venipuncture in acid citrate dextrose(ACD).
2. Centrifuge blood at 700 rpm for 10 min.
3. Remove upper plasma layer that contains platelets. It will be about 1 cm thick.
Put it in a clean eppendorf tube.
4. Platelets:
(a) Centrifuge plasma at 400 g for 10 min.
(b) Pipet plasma out. If pellet (platelets) red, add 1ml of lysis buffer and let
stand for 10 min.
(c) Centrifuge at 400 g for 10 min. Discard supernatant.
(d) Repeat lysis as necessary until pellet is white.
(e) Discard supernatant and add 1ml of PBS. Pipet to mix.
(f) Centrifuge at 400 g for 10 min.
(g) Repeat wash. Discard supernatant.
(h) Resuspend platelets to final concentration.
5. Dilute the lower thick red layer at least 1:1 with PBS. If blood is from PV patient,
dilute even more.
6. Add 3 ml of sterile histopaque into each 15 ml centrifuge tube (one tube for each
8ml of diluted blood).
7. Very slowly add the diluted blood onto the histopaque, making sure they do not
mix. Add no more than 8 ml of diluted blood.
8. Centrifuge at 400 g for 30 min. Ensure NO BRAKE on centrifuge.
9. Mononuclear cells: After centrifugation at 400 g remove the cloudy layer that
contains the mononuclear cells. Put in a clean 15 ml centrifuge tube (no more
than two layers per tube) and fill tube to 15ml with PBS. Mix well.
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(a) Spin down at 400g for 10 min.
(b) Pipet out supernatant. Discard.
(c) Add 2 ml of lysis buffer. Let stand for 10 min.
(d) Centrifuge at 400 g for 10 min. If pellet is red. Repeat lysis.
(e) Discard supernatant. Fill tube with PBS and mix well.
(f) Centrifuge at 400 g for 10 min.
(g) Repeat wash.
(h) Resuspend cells in PBS to final concentration.
10. Granulocytes: Remove the remaining volume to the cell pellet which should be
red and occupy about 2ml.
(a) Add 4 volumes of lysis buffer. Pipet to mix. Let stand for 10 min at room
temperature.
(b) Centrifuge at 2500 rpm for 10 min.
(c) Decant supernatant.
(d) Repeat lysis as necessary (usually 2 or 3 times) until pellet is white,centrifuging
at 450 g for 10 min each time.
(e) Decant supernatant.
(f) Fill tube to 15 ml with PBS and mix well.
(g) Centrifuge at 450 g for 10 min.
(h) Repeat wash.
(i) Resuspend pellet in PBS to final concentration.
3.1.4 Reverse transcription real time polymerase
chain reaction (qRT-PCR)
Real time polymerase chain reaction (PCR), in conjunction with reverse tran-
scription, is a very effective tool to quantify gene expression from ribonucleic acid
(RNA). PCR is a process for (DNA) amplification able to generate large amounts of
the DNA sequence in question (∼ 105copies [8]). The overall process can be divided
into three steps: 1) denaturation, 2) annealing and 3) elongation. During the first
step, double stranded DNA is heated to 94oC. At this temperature the strands will
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separate (denature) allowing primers3 to access the single stranded DNA (ssDNA).
The annealing step consists of cooling the reaction mixture to about 50o. This allows
primers to select and bind to the single stranded DNA template molecules. Finally,
during the elongation step, the reaction solution is heated to 72o, and in the presence
of all nucleotide bases, the heat stable polymerase will drive the replication by reading
the template DNA and synthesizing the new single stranded DNA. Each repetition
of the process will double the amount of DNA.
Amplification of messenger RNA (mRNA) is necessary when quantification of the
expression of a gene is desired. However, RNA is not suitable for amplification by
the DNA polymerases used for PCR, thus making reverse transcription indispensable.
RNA can be reverse transcribed into its complementary DNA (cDNA) using reverse
transcriptase, an enzyme usually obtained from retroviruses.
Unfortunately, accurate quantification of DNA is not possible with normal PCR,
as the final amount of DNA does not necessarily mirror the initial amount of DNA
present in the reaction. This phenomenon is due to many factors including, but
not limited to, deactivation of the polymerase, shortage of nucleotide bases and/or
primers, reannealing of amplified DNA, etc. [9]. To overcome this issue, real time
PCR also known as quantitative PCR (qPCR) was developed in the 90s [10]. The
principle of qPCR is the introduction of a fluorescent probe with two fluorophores
(reporter and quencher) that upon polymerase cleavage, increases fluorescence. See
Figure 3.5.
The fluorescent signal allows real time detection of the amplification process, and
a sigmoidal curve of fluorescence versus amplification cycles is produced see Figure
3.6A. During the first cycles no increased in the fluorescence is detectable. This part
of the graph is called the baseline and is used as the background of the measurement.
Thus, subtraction of the baseline from the measurements yields the absolute increased
in fluorescence. The second part is an exponential increase of the fluorescence. Finally
the curve goes into a nonexponential plateau at higher cycle numbers that occur due to
3ssDNA, usually 18 to 28 nucleotides in length [9] that serve as the starting point for
DNA replication.
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Figure 3.5: Mechanism of the qPCR probe cleavage that results in a fluorescent





Figure 3.6: Amplification plots of A: Real time quantitative PCR; and B: 1:2
serially diluted samples of human DNA samples. Reprinted with permission from [10].
Copyright 1996, Cold spring harbor laboratory press.
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the exhaustion of reaction components (primers, probes, nucleotide bases, etc.). The
amplification plot provides information that allows determination of the quality of the
measurement being done and the final result, which is given as a cycle number (CT )
at which the enough amplified material accumulates to yield a detectable increased
in the fluorescence (see Figure 3.6A). CT value is proportional to the initial quantity
of target DNA used for the amplification [10], see Figure 3.6B.
CT values mainly allow for two types of quantification, absolute and relative.
Absolute quantification is used to determine the number of copies of a particular
gene present in a sample. This requires normalization to an initial known quantity
such as the number of cells or the amount of nucleic acid. Relative quantification, on
the other hand, determines the target gene expression relative to a reference gene.4
The advantage of this method is that it does not require quantification of the initial
amount of material. The pitfall is the need for a reference gene that must have a
constant expression among all the samples tested and for which expression must not
be affected by the different conditions tested in the study such as treatment or the
presence of a disease.
Relative quantification is done by measuring CT for both the target and the
reference genes in the same sample. This allows compensation for differences in the
initial amount of material for each sample. Additional normalization can be done with
respect to a calibrator sample or set, such as healthy (control) or untreated samples.
Therefore, the final result will be given in terms of a fold change in normalized gene
expression of one group (i.e., patients) with respect to another (i.e., controls).
Gene expression of glucose transporter 1 (SLC2A1), vascular endothelial growth
factor A (VEGF-A) and pyruvate dehydrogenase kinase, isozyme 1 (PDK1) relative
to the hypoxanthine phosphoribosyltransferase 1 (HPRT1) housekeeping gene were
measured from RNA from blood cells. The selection of HPRT1 as housekeeping gene
is based on its reported constant expression in neutrophils [12], reticulocytes [13] and
leukocytes, in general [14].
4Also known as housekeeping gene.
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Total RNA from granulocytes was isolated by Tri-Reagent (Molecular Research
Center, Cincinnati, OH). Total RNA (50 ng) was reverse transcribed using Su-
perScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen, Carlsbad,
CA). RNA degradation was checked by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). RNA with well defined 28s and 18s bands in SDS-
PAGE was used. Additionally, the quantity and quality of RNA were checked using
spectrophotometric analysis (NanoDrop, Thermo Fisher Scientific Inc., DE, USA) by
measuring absorption at 230 nm, 260 nm and 280 nm.
Expression of the genes was determined by qRT-PCR using TaqMan Expression
Assays (SLC2A1: Hs00892681 m1; VEGF-A: Hs99999070 m1; PDK1: Hs00176853 m1;
HPRT1: 4333768F) (Applied Biosystems, Foster City, CA). Relative gene expression
was evaluated using Biogazelle QBasePLUS (Zwijnaarde, Belgium).
3.1.5 Samples
“It is the policy of the Institutional Review Board (IRB) that all human subjects
research that is conducted by or under the direction of any employee, faculty, staff,
student, or agent of the University of Utah in connection with his or her institutional
responsibilities must be reviewed by the IRB.”5 The protocols for the research pre-
sented as part of the present doctoral thesis have been reviewed and approved by the
University of Utah IRB.
3.1.5.1 Human whole blood samples from
myeloproliferative patients
This study was previously reviewed and approved by The University of Utah IRB
as a minimal risk study on 6/10/2009 (IRB No. 35136, PI: Josef Prchal). Fresh blood
samples from consented patients with known myeloproliferative disorders (Essential
Thrombocythemia, Polycythemia Vera and Idiopathic Myelofibrosis) were collected at
the University of Utah Hospital and VA Salt Lake City Medical Center. Protocol was
revised to include control samples and reapproved on May 2010. A second revision of
5University of Utah Institutional Review Board Website.
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the protocol was done to include secondary polycythemia and thrombocytosis patients
who were screened as part of IRB No. 17793 and reapproved on May 2011 .
3.1.5.2 Human serum and peripheral mononuclear cells
before and after influenza vaccination
This study was previously reviewed and approved by The Tniversity of Utah IRB
as nonhuman subject research on 10/16/2009 (IRB No. 38405, PI: Valy Vardeny)
to obtain deidentified serum and peripheral blood mononuclear cells (PBMCs) from
patients with heart failure and controls administered during the 2009/2010 influenza
season banked through the IRB project “The use of high dose influenza vaccine
compared to standard dose vaccine in patients with heart failure - a pilot study”
submitted to the University of Wisconsin.
3.1.5.3 Whole blood for hemoglobin variants
Deidentified samples of whole blood from patients affected with hemoglobinopa-
thies were obtained from ARUP Laboratories (Salt Lake City, Utah) under the
approved IRB protocol “Blood, urine and other body fluid samples for validation
of assay methods used in clinical testing” (IRB No. 7275).
3.2 Statistical methods
3.2.1 Hypothesis testing
Hypothesis testing is a statistical tool used to draw inferences about populations
from sets of empirical data. Hypothesis testing can be done on one or multiple sets
of samples. One-sample tests are used to test if a population’s parameter, usually
the mean or the median, is different from a set value. On the other hand, two
or more sample sets tests are used to test whether the compared populations have
different parameter values. Hypothesis testing starts by making a statement about the
populations that are to be tested. This statement is called the null hypothesis(H0),
and it is, in principle, an assertion that one can only disprove. That means that
the test has only one of two possible outcomes: rejecting H0 or failing to reject H0.
A parameter of a population can be tested under the hypothesis that it is less or
larger than some value. Such a test is known as a one-tailed test, as the region of
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rejection is only one side of the sampling distribution. On the other hand, when the
hypothesis is that the parameter is exactly equal to some value, the test is said to
be two-tailed. Interpreting results from hypothesis testing is often done in terms of
the p-value. P-value is the probability that, for other sampling, one obtains data at
least as extreme as the one that was observed, assuming that the null hypothesis is
true. Therefore, small p-values suggest H0 is unlikely to be true. H0 is rejected if the
p-value is less than the significance level (i.e., critical p-value). Among the scientific
community, a 5% or 1% significance level is often adopted.
There are multiple methods for hypothesis testing. They differ in the assumption
made a priori about the distributions of the variables under study. Most common
tests assume normal distributions and are called parametric tests. Another common
assumption is homoscedasticity (equal variances of the tested distributions). Before
using any of the tests, it should be clear whether the data complies with the assump-
tion made by the them. This can be done by testing normality and homoscedasticity
using the Kolmogorov-Smirnov test and the Levene’s tests, respectively. Table 3.1
shows some of the tests and their respective assumptions.
Hypothesis testing is used in Chapter 4 to test whether spectroscopic variables
measured on healthy and diseased samples come from the same population, meaning
the null hypothesis is that healthy and diseased populations have the same mean or
median and that we should used two-tailed tests. Variables were tested for normality
and homoscedasticity. Either Kruskal-Wallis or the t-test for unequal variances was
used, accordingly. We repeat this procedure for thousands of variables measured on
Table 3.1: Hypothesis testing methods and their assumptions made on the distribu-
tions of the variables tested.
Test Parameter Tested Assumptions
Analysis of variance Means Normality and homoscedasticity
t-test Means Normality and unknown
but equal variances
t-test(unequal variances) Means Normality
Kruskal-Wallis Medians Equal continuous distributions
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the same set of samples. This introduces an additional problem described as follows:
The more tests we performed on a data set, the more likely we were to reject the
null hypothesis when it is true [15]. To overcome this problem one must adjust
the significance level and make it more stringent. One way to do this is using the






where C is the number of tests done on the set of data.
3.2.2 Receiver operating characteristic curve
Receiver operating characteristic (ROC) curves are a beautiful way to visualize
binomial (positive or negative) classifiers based on their performance, which is often
defined in terms of sensitivity and specificity. Sensitivity is a measure of the classifier’s
ability to identify positive cases (eq. 3.3), while specificity is a measure of the ability
to identify negative cases (eq. 3.4):
sensitivity =
True Positives




True Negatives+ False Positives
(3.4)
The ROC curve is a plot of sensitivity (i.e., True positive rate) versus 1-specificity
(i.e., False positive rate) for different cut-off points, and thus it renders the tradeoff
between sensitivity and specificity. The point (0,1) represents the ideal classifier.
That is, no false negatives or false positives are assigned by the classifier. Since in
practice this is not achieved, the best cut-off point is defined as the point on the ROC
curve with the shortest distance away from the ideal classifier. Figure 3.7 shows a
sample ROC curve where the diagonal line represents a random classifier and the blue
point is the best cut-off.
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Figure 3.7: Example of an ROC curve (red). Diagonal line corresponds to random
classifier. Blue dot is the cut-off point defined as the closest to the ideal test point.
In order to compare the performance of multiple classifiers or tests, the area under
the curve (AUC) is calculated. The AUC has values between 0 and 1, but since the
random classifier (defined by the diagonal of the unit square) has an AUC=0.5, a
useful test should never have an AUC lower than 0.5.
The AUC is equivalent to the probability that the test will rank a randomly chosen
positive case higher than a randomly chosen negative case [16]. Thus, in general,
the higher the AUC is the better the classifier’s performance is. Table 3.2 shows
the standard adopted by the medical sciences community to evaluate a classifier’s
performance based on AUC values [17–19].
In Chapter 4, ROC curves are use to evaluate the performance of various spectral
variables to distinguish among healthy and diseased subjects. Unless otherwise noted,
diseased subjects are defined as positive and healthy subjects are defined as negative
cases.
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Spectroscopic data are multivariate in nature, meaning that the underling phe-
nomenon is described by more than one variable. In the spectroscopic case, we
have values (I) measured in units of light intensity or photon count, for a set of
n wavelength, frequency or energy points. If each I(ωn) is considered a variable, a
spectrum is then a multivariate set and multiple spectra can be analyzed under the
multivariate analysis (MVA) framework.
Multivariate data analysis can be classified in three groups according to its final
purpose [20]: Data description, discrimination and classification, or regression and
prediction. Data description is concerned with the exploration and characterization
of the data that could be done in term of means and standard deviations or corre-
lations between variables, as well as finding which variables are the most relevant to
describe the phenomenon under scope. Discrimination and classification of data
are done to separate and to classify samples based on a set of variables and some a
priori knowledge of the samples (e.g., healthy or diseased sample). The most popular
technique for data description and classification is principal component analysis, and
it is explained in more detailed below. Finally, a mathematical model or regression
can be constructed based on variables measured on a training set of samples from
which some additional knowledge is available. It can then be applied to a new set of
samples to calculate an indirect property. Some regression and prediction techniques
are Principal Components Regression and Partial Least Squares Regression.
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3.2.3.1 Principal components analysis
Principal component analysis (PCA) is a very powerful application of linear al-
gebra. One of its more important strengths is that it is nonparametric. As such,
PCA results and capabilities do not change upon variables’ distributions. The main
objective of PCA is to compute the most relevant algebraic basis to represent and to
attain the most information out of the data.
PCA works as a linear transformation from the space of variables with m dimen-
sions (where m is the number of variables, and each sample is represented as an
m×1 vector) to a new space that represents the data in a more meaningful way. The
problem is that there are many changes of basis that one could use. This problem
is solved by assuming that the directions within the data with maximum variance
are the ones that carry most of the information. Figure 3.8A shows a set of data
represented in a 3-dimensional space of variables. The data set displays most of the
variability along the line depicted in red. Such a line would constitute the first axis
of the new space, also known as the first principal component.
Mathematically, PCA starts with the construction of the matrices Xm×n, where
each column corresponds to the set of measurements of a sample and the covariance
matrix CX (eq. 3.5) [21]. CX is a square symmetric m ×m matrix whose diagonal
terms correspond to the variances of the m variables and the off-diagonal elements to





The optimal basis is the one that makes CX diagonal, that way all newly defined
variables will be independent from each other, and variances of each new variable
will be maximized. In the basis where CX is diagonal, the basis vectors correspond
to the principal components and they will lie in the directions of maximum variance,




T is diagonal. The rows of P are the principal components (PCs)
of X [21]. It is useful to subtract the mean of each variable from each row of Xm×n,
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A B
Figure 3.8: Principal component analysis. A: Data points in a 3-dimensional
variable space. Red line shows the direction of most variability within the data. B:
Different set of data point that show a different distribution in the variables space.
Whereas in A most of the variance can be describe along one direction (i.e., one PC),
in B two PCs are required.
making the origin of the PCs the center of gravity of the data as depicted in Figure
3.8B in the case of 3-dimensional space. One of the most useful features of PCA is
the reduction of dimensionality of a data set, that is, to elucidate the variables that
mostly contribute to describe the variance among the data. For example, in Figure
3.8B, it is observable that most of the variance in the data is along the first and second
principal components, while the third is almost negligible. In that case we have been
able to go from a 3-dimensional to a 2-dimensional space, which might seem not that
useful. However, in Chapter 5 we will show that PCA analysis allows reduction from
a 1024-dimension space to a 2-dimensional space.
In practice PCA is done with help of two very useful plots: the loadings and the
scores plot. The PCs are vectors in variable space that are expressed as a linear
combination of the unit vector (i.e., each variable vector). The coefficients that
describe that linear combination are the loadings such that each PC will have m
corresponding loadings. The loading plot is usually a 2-dimensional map of the
variables in which each variable is represented by a pair of loadings (see Figure





Figure 3.9: Examples of PCA plots used for the analysis of data. A: Loadings
or variables map for two PCs. B: Scale independent variables plot used to assess
intervariable relations. C: Scores or samples plot for the same PCs as in A. PCA was
done using The Unscrambler [22] with software’s example data set.
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but a more useful plot is the correlation loadings plot which depicts loadings in a
scale-independent fashion so relations between variables are easily assessed. Figure
3.9B is the correlation loadings plot of the data in Figure 3.9A. The variable V8 is the
one that contributes the most to PC1 whereas V3 is the one that most contributes
to PC2, variables V9, V10 and V11 contribute very little to either PC. Additionally,
one observes from 3.9B that V7 and V8 are highly positively correlated while V3
and V12 are highly negatively correlated. From 3.9A and 3.9B one could conclude
that variables V2, V3, V7, V8 and V12 will suffice to describe most of the variability
among the data.
A scores plot or samples mapping depicts each sample in the PCs space. Objects
close to the origin are the most typical whereas the ones far from it are extremes.
Objects close to each other in the scores plot are similar. This property of the scores
plot makes PCA viable for discrimination and classification of data. PCA is used in
Chapter 5 for the analysis and classification of multiple SERS spectra.
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CHAPTER 4
SURFACE ENHANCED RAMAN SPECTROSCOPY
ON MYELOPROLIFERATIVE NEOPLASMS1,2
4.1 Introduction
Myeloproliferative neoplasms (MPNs) belong to a family of diseases that originate
in a somatic mutation in a self-renewing hematopoietic stem cell. MPNs include
four main diseases: chronic myelogenous leukemia (CML), which is characterized by
Philadelphia chromosomal abnormality; polycythemia vera (PV); essential thrombo-
cythemia (ET); and primary myelofibrosis (PMF). In this study, we focused on so
called Philadelphia chromosome negative disorders: PV, ET and PMF. Characteris-
tics of these diseases are bone marrow hypercellularity, predisposition to thrombosis
and hemorrhage, and an increased risk of evolution towards universally fatal acute
leukemia [1, 2]. These three MPNs share, in a variable proportion of each group, a
somatic clonal mutation of a tyrosine kinase gene that encodes for JAK2 V617F [3].
While this mutation is diagnostic for the presence of an MPN, but not its type, its
absence does not exclude the existence of MPN [4]. In JAK2 V617F negative patients,
the diagnosis of PV and ET may be challenging and in some instances, may be difficult
and expensive to differentiate from reactive polycythemic, nonmalignant disorders
and congenital polycythemias, whereas ET is largely diagnosed by exclusion of other
conditions with increased platelet count due to the ‘lack of specific tests’ [4,5]. More
1 Parts of this chapter were submitted in September 2011 as an article to Science,
coauthored with Professor Valy Vardeny, Professor Sabina Swierczek and Doctor Josef T.
Prchal from the Division of Hematology, School of Medicine at the University of Utah.
2 Parts of this chapter resulted in US patent application 61/428,697 (December 2010,
see Appendix) coauthored with Doctor Josef T. Prchal and Professor Valy Vardeny.
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detailed molecular basis of MPNs and current diagnosis strategies are both found in
Section 2.4.
In recent years, Raman spectroscopy has proven to be a successful diagnosis
technique of a wide range of diseases including atherosclerosis, kidney stones, bone
diseases, diabetes, and a broad collection of neoplasms [6]. Optical spectroscopy
has several advantages over more traditional diagnosis methods (i.e., histopathology,
quantitative PCR, etc.) such as faster data analysis; nonspecific sample preparation;
nonspecific labels/reagents/antibodies requirements; and immediate on-site imple-
mentation.
Raman scattering can be described as the inelastic scattering of an impinging
photon by a molecule. The energy shift of the scattered photon usually corresponds
to a vibrational mode of the molecule. Various Raman active vibrational modes cause
different photon energy shifts. Thus, the Raman scattering spectrum is highly specific
to a molecule, as each type of molecule has a distinctive set of vibrational modes (see
Section 1.2). However, the Raman scattering cross section is very small, and this
usually requires an enhancement mechanism. Raman scattering can be enhanced
in the vicinity of subwavelength size metallic nanoparticles or rough surfaces [7],
giving rise to surface enhanced Raman scattering (SERS). The enhancement is mainly
electrostatic in nature, although there is a chemical contribution that results from the
adsorption of molecules onto the metal surface [8](see Section 1.3).
As describe in section 2.3, the so called Warburg effect is associated with increased
activity of hypoxia regulated transcriptional factors, i.e., HIF-1 and HIF-2 that bind
to evolutionarily conserved oligonucleotides of their target genes. It is an adaptive
response that leads to augmentation of aerobic glycolysis in cancer tissues, which
in turn, makes cancer cells consume more glucose under aerobic conditions than
normal cells. This is a response mediated by the hypoxia induced transcription factor
(HIF) [9].
The analysis of SERS spectra from granulocytes reveals that it is possible to detect
differences among MPN patients and healthy controls. This represents a radical
change in the diagnostic approach currently used for differentiation of neoplastic
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from reactive and congenital disorders. The experimental conditions for the SERS
measurements and SERS spectrum analysis can be easily achieved, laser induced
damage to the sample can be neglected, and results may be rapidly obtained. In this
chapter, we show that SERS background continuum carries very valuable information
that allows optical diagnosis of MPN. The described technique involves straight
forward substrate and sample preparation, and allows fast diagnosis. Moreover, we
provide supporting evidence that MPN, similar to other malignancies, modify their
metabolism by the Warburg effect.
4.2 Study subjects
Our study includes three groups of subjects: (1) Healthy subjects who did not have
any active medical problem and had normal blood counts; (2) Males and females with
myeloproliferative neoplasms (all had well characterized myeloproliferative disorders
as per World Health Organization criteria [10], namely PV, ET, and PMF) and
(3) controls with reactive nonneoplastic individuals with elevated platelets wherein
ET was ruled out (reactive thrombocytosis) and reactive (nonPV) polycythemias.
After informed consent, 5 to 8 ml of peripheral blood was collected by venipunc-
ture. The granulocytes fraction was isolated by gradient medium (Histopaque 1077,
Sigma Aldrich) (see Section 3.1.3). This study was reviewed and approved by the
institutional review board from the University of Utah (see Section 3.1.5). Table 4.1
summarizes the baseline information from subjects recruited for the study.
4.3 Methods
Confocal microspectroscopy configuration was used for hyperspectral imaging and
acquisition of spectra, as described in Section 3.1.1, using 60X (NA 0.80) and 10X
(NA 0.25) microscope objectives, respectively. Silver nanoparticles deposited on glass
were prepared by the Tollens reaction as explained in Section 3.1.2 with a 120-second
reaction time. Substrates were stored no longer than 1 day under nitrogen atmosphere
from the time of preparation until their use. Granulocytes and mononuclear cell
fractions were isolated by centrifugation with a density gradient medium (Section
3.1.3). Solutions of cells of at least 106cells/ml but no more than 107cells/ml,
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Table 4.1: Baseline characteristics of subjects enrolled in the study.
Patients (n=75) Controls (n=11)

























were prepared in phosphate buffered saline (PBS) and stored at 4 oC until optical
measurements were done, which was typically within 24 hours of preparation.
Right before the spectroscopic measurements, one or two drops of the cell solution
were placed onto the silver substrate. With the help of a clean coverslip the liquid
was carefully smeared and later blow-dried with nitrogen gas until most of the excess
water was removed but not completely. The substrate was rinsed with distilled water
to removed salt crystals left by the PBS and blowdried with nitrogen gas, again, until
most of the excess water was removed but not completely. Figure 4.1 shows light
microscope images of granulocytes onto silver substrates after sample preparation.
Successful sample preparation would yield cells that look well defined under the
light microscope (Figures 4.1A and 4.1B). Improper storage, nongentle smear and/or
overdrying cause cell lysis and nonwell defined structures may be observed, as shown
in Figure 4.1C. Additionally, if concentrations of cells solutions are too high, they tend
to aggregate and form bigger structures where single cells are difficult to recognize.
Spectra from granulocytes and mononuclear cells from human subjects were ac-
quired. Dark current and cosmic rays artifacts were removed from each spectrum,
after which a Savitzky-Golay filter (4th Order, Zero Derivative)was applied.
A B C
Figure 4.1: Light microscope image of granulocytes onto silver nanoparticles
deposited on glass with A: 10X magnification (scale bar= 100µm) and B: 60X
magnification . C: Unsuccessful sample preparation (scale bar= 20µm)
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4.3.1 Clonality studies
All studied females were evaluated for clonality of granulocytes, which was es-
tablished by the genotyping of 5 X chromosome exonic polymorphisms followed by
determination of the informative heterozygous X chromosome allelic mRNA usage
ratio by quantitative real-time AS-PCR (qAS-PCR), as described in [11].
We previously established that exonic SNP polymorphic X chromosome allelic
frequency utilization greater than 90% is an indicator of the clonal phenotype [12,13].
4.3.2 JAK2 mutational analysis
The JAK2 V617F mutational burden in separated peripheral blood cells was deter-
mined by quantitative allele specific PCR (qAS-PCR). The JAK2 V617F mutation
was established by qAS-PCR utilizing mutation specific primers containing locked
nucleic acid and a mismatched nucleotide [11,14].
4.4 Carbonization and silver oxides: setting up the
experimental conditions
The SERS signal is often obscured by the appearance of two broad vibrational
bands that are associated with the presence of amorphous carbon structures. The
origin of the amorphous carbon is usually attributed to analyte decomposition caused
by heat (i.e., pyrolysis or carbonization), catalytic activity of the substrate, or by
contamination from carbonaceous species [15,16].
The formation of amorphous carbon from methylene blue (C16H18N3SCl) on the
Tollens substrates described in Section 3.1.2 was observed as a function of time and
excitation intensity. For this study, a solution of methylene blue in ethanol was
prepared and drop casted onto the substrate. The SERS spectrum of methylene
blue is shown in Figure 4.2A. Figure 4.2B shows the spectrum of methylene blue
after 250 seconds of exposure under 2.1 mW excitation power (λexc = 488nm). The
transformation to an amorphous carbon structure is evident by the the vibrational
bands at ∼1360 cm−1 and ∼1580 cm−1. The bands at ∼500 cm−1 and ∼900 cm−1
are assigned to oxidation of the substrate, specifically AgO and Ag2O [17, 18].




Figure 4.2: SERS spectrum of methylene blue (C16H18N3SCl) A: on Tollens
substrate with laser wavelength 488nm (0.24 mW, 60X microscope objective) and
B: after 250 seconds of exposure under 2.1 mW excitation power.
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of this are shown in Figures 4.3A and 4.3B with excitation power of 0.24 mW
and 2.1 mW, respectively. In Figure 4.3A, the spectrum does not change in time,
whereas in Figure 4.3B, the appearance of the spectral features described above is
observed. Figure 4.4A shows the time dependence of the total emission intensity
(TEI), normalized to t=0, for various excitation intensities, which has been fitted
by an exponential of the form TEI(t) = T0exp(−t/τ) + c. The time parameter τ is
plotted in Figure 4.4B as function of excitation intensity. Only with very low intensity
(≤ 0.21mW ) the formation of amorphous carbon is not observed.
SERS spectra from granulocytes exhibit a similar time dependence as observed
in methylene blue with a very important difference. There is an initial period of
time of about 10 seconds for which the spectra is unchanged, as shown in Figure 4.5.
Measurements on cells are limited within that period of time. Thus, the integration
time per accumulation was set to 0.1 seconds and 10 accumulations per spectra were
acquired, making the measurement about 1 second long.
Contamination by carbonaceous species is one of the major problems encountered
when doing SERS [15, 16, 19]. Some authors even claim the presence of amorphous
carbon to be ubiquitous in SERS, especially if silver substrates are used [16, 19].
Protocols aimed to clean the substrates have been largely studied with various rates
of success [20]. It was determined by energy dispersive X-ray spectroscopy (EDS,
10kV accelerating voltage)3 that UV-ozone cleaning protocol did not reduced the
amount of carbon present on the substrate, but it increased the amount of oxygen
(see Table 4.2). The increased oxygen amount was attributed to oxidation of the
silver induced by the UV radiation [21]. Given these results, a cleaning protocol was
not adopted; instead the substrates were freshly prepared before measurements and
used within a couple of hours of the preparation.
The presence of the two broad vibrational bands associated with silver oxide
described above was also observed when measurements were performed under nitrogen
atmosphere, suggesting that silver oxide was present before the measurements and




Figure 4.3: SERS spectrum of methylene blue as a function of time under A:




Figure 4.4: Dynamics of the SERS spectrum of methylene blue. A: Total emission
intensity, normalized to t=0, as a function of exposure time for various excitation
intensities (shown in mW). B: Each curve in A was fitted to an exponential of the
form TEI(t) = T0exp(−t/τ) + c. Fitting parameter τ is shown as a function of
excitation intensity.
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Figure 4.5: Typical total emission intensity as a function of time from a human
granulocyte lying on top of a Tollens substrate(10X Microscope Objective, 3.5mW
excitation power and 488nm excitation wavelength)
Table 4.2: Weight percentage as measured by EDS of Tollens substrates before and
after 30 seconds of UV-Ozone exposure.











probably formed immediately after the Tollens reaction took place. This fact made
the use of a nitrogen atmosphere ineffectual as it did not prevent the formation
of silver oxides. Therefore, the SERS measurements were performed under normal
atmospheric conditions.
4.5 SERS on human granulocytes: results
The emission spectrum was measured at the single cell level under the conditions
described above. Figure 4.6 shows the average spectra for each of the four groups,
namely ET, PV, PMF and Control. The bands centered at ∼500 cm−1 and ∼1000
cm−1 are assigned to AgO and Ag2O in the substrate [17, 18]. The emission spectra
also show the formation of an amorphous carbon structure, as evident by the vibra-
tional bands at ∼1370 cm−1, also known as the D-band, and ∼1600 cm−1, also known
as the G-band [18, 22, 23]. In addition, the spectra also contain a broad background
emission in the range of 500-4500 cm−1 discussed in more detail below.
Quantification of spectral differences between affected and healthy subjects was
done by statistical analysis of the total emission intensity (after normalization to
the vibrational band centered at ∼500 cm−1), as well as ratios of integrated in-
tensity over paired scattering frequency intervals. For each subject, average values
from all granulocytes were calculated. For each defined quantity, ratio and total
integrated emission, normality and homoscedasticity were evaluated using the mod-
ified Kolmogorov-Smirnov and the Levene test, respectively. Significant differences
between controls and patients were calculated by the nonparametric Kruskal-Wallis
test or the student’s t-test for unequal variances, as necessary. For ratios of intensity,
significant level was adjusted to multiple comparisons (see Section 3.2.1). P-values
below 0.0004 were considered significant; for any other variable, the significant level
was set to 0.05.
We found that the TEI is statistically significantly higher in control subjects
than in MPN patients (p-value< 0.0014) and in reactive nonneoplastic subjects (p-
value< 0.05), but not among all three tested MPNs (Figure 4.7). We identified three
viable intensity ratios that displayed significant differences not only between controls
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Figure 4.6: Average emission spectra from granulocytes from all controls (black),
ET (red), PV (green) and PMF (blue) patients. The emission spectrum from the
substrate is shown in magenta. The emission spectrum from the substrate is shown
in magenta. The emission spectra were normalized to the Raman peak at ∼500 cm−1
that originates from silver oxides in the substrate. The broad road emission bands





Figure 4.7: Box plots of A: normalized total emission intensity for controls,
MPN patients and reactive nonneoplastic subjects, respectively; and B: normalized
integrated emission intensity for each MPN; the accompanying numbers denote the
number of specimens. The top and bottom boxes correspond to the first and third
quartile, respectively. The whiskers lengths are 1.5 times the interquartile range.
P-value is the probability that the two populations come from distributions with the
same mean ratio. Crosses are outliers.
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and MPN patients, but also between ET and the other MPN patients (see Table 4.3).
This is of particular importance because ET is largely diagnosed by exclusion. A
total of 17 different emission intensity ratios were identified that showed significant
discrimination between patients and healthy subjects (Table 4.4). These 17 intensity
ratios come from six frequency ranges paired in three groups (see Figure 4.8).
We explored the potential of the total integrated intensity and intensity ratios
obtained from SERS spectra of granulocytes as markers for MPNs. As described
in Section 3.2.2, tests with areas under the receiver operating characteristic (ROC)
curve larger than 0.8 are considered very good, whereas tests with areas under the
curve (AUC) larger than 0.9 are considered excellent. The ROC curve indicates that
the total integrated emission intensity is a good test for the presence of an MPN
with an AUC of 0.818 (95% CI: 0.707 - 0.930). See Figure 4.9. At the cut-off
point, sensitivity is 82.3% (95% CI: 72.7% - 91.8%) and specificity is 72.7% (95%
CI: 46.4% - 99.0%). ROC analysis for all intensity ratios that exhibit a significant
difference between controls and MPN patients (p-value< 0.0004) is shown in Table
4.4, where AUC, sensitivity and specificity at the cut-off point are listed. The ROC
curves reveal that intensity ratios in Table 4.4 are excellent tests for the presence of
an MPN, as they have an AUC larger than 0.9, and provide higher specificity and
sensitivity than the total integrated intensity. The ROC curves of the best performing
ratios from each of the frequency intervals pairs are shown in Figures 4.10 and 4.11.
Although some intensity ratios show a significant difference among ET and the other
Table 4.3: P-values as found by Kruskal-Wallis test. Groups are defined as MPN
patients versus controls (P vs C) and ET patients versus both PV and PMF patients
(ET vs PV,PMF).
Frequency Frequency
Interval 1 Interval 2 p-value p-value
Pair (cm−1) (cm−1) P vs C ET vs PV, PMF
15 1384 - 1863 3238 - 3624 0.0002 0.0409
16 1138 - 1674 2833 - 3078 0.0004 0.0367




































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.8: Paired areas from where ratios of integrated emission intensities showed
statistically significant difference between control group and patients (blue, red and
green) and between ET patients and PV,PMF patients (green).
Figure 4.9: ROC (Receiver operating characteristic) curve for the total emission
intensity. Blue dot is the cut-off point defined as the closest to the ideal test point.
At cut off point sensitivity is 83.1% (95% CI: 73.5% - 92.6%) and specificity is 72.7%





Figure 4.10: Statistical analysis for best performing ratios Left Column: Ratio
identification number as defined in Table 4.4. Middle column: Ratios of integrated
intensity for controls and MPN patients. The top and bottom boxes correspond
to the first and third quartile, respectively. The whiskers lengths are 1.5 times the
interquartile range. P-value is the probability that the two populations come from
distributions with the same mean ratio. Crosses are outliers. Right Column:
ROC curve for ratios of intensity. Blue dot is the cut-off point defined as the
closest to the ideal test point. Sensitivity and specificity are shown at cut-off point.




Figure 4.11: Statistical analysis for best performing ratios Left Column: Ratio
identification number as defined in Table 4.4. Middle column: Ratios of integrated
intensity for controls and MPN patients. The top and bottom boxes correspond
to the second and third quartile, respectively. The whiskers lengths are 1.5 times
the interquartile range. P-value is the probability that the two populations come
from distributions with the same mean ratio. Crosses are outliers. Right Column:
ROC (Receiver operating characteristic) curve for ratios of intensity. Blue dot is the
cut-off point defined as the closest to the ideal test point. Sensitivity and specificity
are shown at cut-off point. Negative=Control, Positive=MPN patient. AUC=Area
under the curve.
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two disorders (p-value< 0.05), when the ROC curve was evaluated with ET patients
as positive cases and PV and PMF patients as negative, a diagnostic value was not
found (AUC< 0.7).
Figure 4.12 shows the cross correlation coefficients between ratios of intensity,
total emission intensity and clinically relevant variables (age and JAK2 V617F allelic
burden) for all subjects. Correlations between JAK2 V617F allelic burden and total
emission intensity or spectral ratios were not found. A slight correlation between
age and spectroscopic variables was found (smaller that 0.41). Correlations between
ratios and TEI are moderate (less than 0.8), while correlations between ratios 1-14
are very strong (larger than 0.8). Ratio 17 (see Table 4.3) is weakly correlated to
all of the other variables (< 0.65) except for ratios 15 and 16 with which it is highly
correlated (> 0.89). High correlations among ratios 1 to 14 agree with them having
the same origin in the broad continuum.
The surfaced enhanced emission spectra from granulocytes are composed of two
parts: (i) a broad luminescent background (also known as the continuum spectrum
in the literature), and (ii) Raman scattering vibrational bands associated with vi-
brations of amorphous carbon and silver (I, II) oxide. In order to separate the two
emission components, we used the algorithm described by Zhao et al [24], with a third
order polynomial. Figure 4.13A shows the average spectra of each of the populations
studied. Figure 4.13B shows the background continuum component, and Figure 4.13C
shows the vibrational Raman scattering contribution of each of the populations. The
continuum spectrum of the patients displays a blue shift compared to that of controls,
as indicated by the spectral position of the maximum (Figure 4.13D); the continuum
spectrum for ET patients shows the least shift, whereas the spectrum from PMF
patients shows the most shift.
A control experiment was performed for studying the underlying mechanism for
the spectral shift obtained in MPN patients. We incubated granulocytes with vari-
ous concentrations of 2-deoxy-D-glucose (2DG), which is a glucose molecule that is
phosphorylated by glucose hexokinase into 2-deoxyglucose-6-phosphate (2D6G) and
thus cannot undergo further glycolysis. 2D6G accumulates in the cell and may serve
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Figure 4.12: Crosscorrelation matrix for ratios of intensity, total emission intensity
and clinically relevant variables, age and JAK2 V617F allelic burden for all subjects














































































































































































































































































































































a measure of cellular glucose uptake [25].
Granulocytes isolated from a healthy subject were incubated for 15 minutes at
37oC with 2DG solutions in PBS. Briefly, after isolation, cells solution was divided
into four identical aliquots and centrifuged at 400 g for 10 min. Pellets were resus-
pended in 1 ml of 1 mM, 5 mM and 10 mM 2DG solutions. The fourth aliquot
was resuspended and incubated in 1ml of PBS without 2DG to be used as a control.
Optical measurements were performed within 4 hours of incubation. SERS spectra
were obtained and postprocessed under the conditions described above (Section 4.3).
We found that the emission background contribution to the SERS spectra from
granulocyte is blue shifted with increasing concentrations of 2DG (Figure 4.14D).
This suggests that the blue shift in the background continuum spectrum may be
explained in part by changes induced by higher glucose uptake in the MPN patients’
cells.
4.5.1 Time resolved spectroscopy from granulocytes
We believe the broad continuum emission observed in the granulocytes spectra
from healthy subjects and patients is due to a photoluminescent process. To corrob-
orate this statement, time resolved measurements of the emission from granulocytes
on the Tollens substrate were acquired using the second harmonic from a tunable
Ti:Sapphire laser (140 fs pulse duration, 80 MHz repetition rate) and a streak camera
(∼5 ps time resolution) synchronized to the excitation pulse train. The sample was
illuminated at a 30 o angle (with respect to the normal), and collection was done in the
normal direction with a microscope objective (NA 0.55). After appropriate filtering of
the excitation light, the emission was dispersed using a 50 grooves/mm grating (600
nm blaze wavelength) onto the streak camera. The excitation power was set to ∼10
mW and two excitation wavelengths were used, 488 nm and 458 nm, respectively.
Additionally, long exposure/long integration time measurements (Int Time ∼2 sec)
were done using 488 nm and 458 nm excitation wavelength from the Ti:Sapphire
laser; collected light was dispersed onto a CCD camera (thermoelectrically cooled to
-30 oC) using a 150 grooves/mm grating (500 nm blaze wavelength).






































































































































































































1300-1600 cm−1, when using 488 nm excitation wavelength, are due to vibrational
raman scattering. As observed in Figure 4.15, the relatively sharper features in the
510-540 nm region from the cell’s spectrum are observed under 488 nm but not under
458nm excitation wavelength. On the other hand, the broad continuum spectrum is
still present, confirming its nonvibrational origin. Additionally, the emission spectrum
from the substrate (i) has lower total emission when compare to that for the cell
(lying on top of the substrate), and (ii) displays no vibrational bands, suggesting
that most of both components, the luminescent and the vibrational contributions to
the measured spectra, arise from the cell or the cell-metal interface.
Further confirmation of the luminescent origin of the broad continuum spectrum
is given by the time resolved measurements done on a granulocyte shown in Figure
4.16A. The peaks shifted from the excitation wavelength appeared only in the instan-
taneous spectrum, expected for raman bands, whereas the delayed emission spectrum
displays the broad continuum (Figure 4.16B) [26]. Moreover, the interval 509 to 528
nm (equivalent to ∼1000 to 1500 cm−1) showed a faster decay than the rest of the
spectrum (Figure 4.17).
4.6 Expression of Hypoxia Induced Factor targets
Hypoxia Induced Factor (HIF) expression is induced in a variety of cancer cells due
to neoplastic metabolic alteration or as an adaptive response that leads to augmen-
tation of aerobic glycolysis or Warburg effect in cancer tissues. This transformation
results in cancer cells consuming more glucose under aerobic conditions caused by
upregulation of HIF transcription factor [9].
Under the hypothesis that MPNs may display Warburg effect we investigated the
expression of hypoxia induced factor-1 (HIF-1) targets: SLC2A1 (glucose transporter
1) and PDK1 (pyruvate dehydrogenase kinase, isozyme 1 ) [27] and hypoxia induced
factor-2 (HIF-2) and HIF-1 target VEGF-A (vascular endothelial growth factor A)
[28]. SLC2A1 gene codes for a major glucose transporter GLUT1 normally expressed
in erythrocytes and endothelial cells [29]. It has in been shown to be upregulated in




Figure 4.15: Long exposure/long integration time spectra of a granulocyte onto
silver nanoparticles substrate and substrate itself, acquired using 488 nm and 458 nm
ps excitation wavelengths A: as a function of wavelength and B: as a function of




Figure 4.16: Time dependence measurements on granulocytes. A: Time resolved
spectra from a granulocyte onto Tollens substrate generated with 488nm pulsed
excitation wavelength. B: Integrated instantaneous (0 to 8ps) and delayed (8 to
140 ps) spectra.
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Figure 4.17: Time dependence measurements on granulocytes. Normalized intensity
decay of two wavelength intervals in the spectrum, plotted in logarithmic scale.
invasiveness and poor prognosis in various neoplasms [30–33]. PDK1 genes codes an
isozome of the pyruvate dehydrogenase kinase (PDK). The role of PDK is an enzyme
that phosphorylates pyruvate dehydrogenase, which in turn inactivates it. Pyruvate
dehydrogenase is one of the enzymes that make up part of the pyruvate dehydrogenase
complex, which plays an important role in the conversion of pyruvate into Acetyl-CoA
(see Section 2.3.2). PDK1 has been shown to be critical for the attenuation of the
production of reactive oxygen species in the mitochondria, maintenance of ATP level
and adaptation to hypoxia [27]. Finally, VEGF-A codes for a mitogen protein that
promotes the growth of new blood vessels.
We did not find a significant difference in VEGF-A expression in MPN patients
when compared with the control group. In contrast, we found that SLC2A1 is upregu-
lated in MPN patients, whereas PDK1 is downregulated (Figure 4.18). Dysregulation
of SLC2A1 and PDK1, both of which are along glycolytic pathways, could in turn
account for higher glucose uptake and changes in the rates at which pyruvate is
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Figure 4.18: Gene expression of PDK1 and SLC2A in granulocytes from ET, PV and
MF patients and controls. ∗, ∗∗ and ∗∗∗ correspond to p-value< 0.05, p-value< 0.01
and p-value< 0.005, respectively, when compared to control group.
converted to Acetyl-CoA and lactate.
4.7 Discussion
The surface enhanced emission spectra measured in granulocyte has two distinctive
features: (i) vibrational bands that originate from amorphous carbon structures and
silver (I, II) oxide, and (ii) a broad background continuum. We showed that the broad
continuum observed from granulocytes is luminescent in origin, as demonstrated by
spectra acquired using different excitation wavelengths and time resolved measure-
ments. Separation of the two contributions reveals that significant differences between
MPN patients and controls arise primarily from the background continuum. For the
background continuum emission, we observed a blue shift in the spectral maximum
and different normalized intensity in patient groups with respect to those in the
control group. The same behavior is observed in granulocytes incubated with higher
2DG concentrations. Although the origin of the background continuum emission in
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SERS is still debated [8,18,26,34], it could, in part, be attributed to surface enhanced
luminescence [8] of molecules close to the metallic surface (within ∼20 nm). We note
that the continuum emission background is known to increase upon adsorption [8]
and, under some experimental conditions, its spectral characteristics depend whether
the molecule involve is an electron-donor or an electron-acceptor [34].
We believe that the background emission we observed is due to enhanced fluores-
cence of flavin adenine dinucleotide (FAD), which explains a lower maximum value
of the background in patients’ spectra as lower FAD levels have been measured in
various neoplastic cells lines [35]. In correlation with the 2DG control measurements,
we believe that the blue shift of the continuum background for MPN patients is
due to the changes in the dielectric constant (m) of the environment surrounding the
metal-cell interface. A portion of the fluorescence emission is from a discrete electronic
excited state of specific, as of yet unidentified molecules close to the metal surface. If
the molecules are electron donors or acceptors with respect to the silver nanoparticles,
then a charge transfer exciton (CTE) is formed at the cell/silver interface. The
CTE level depends on the dielectric properties of the environment, and this in turn
changes the emission spectrum from such a state. Neoplastic cells are known to
have a higher m than normal cells [36]. This change in m, which could be due to
alterations in the concentration of glycolytic metabolites and protein content [36,37],
may directly change the continuum emission spectrum and thus explain the observed
blue-shift. Vibrational bands at ∼1600 cm−1 and ∼1370 cm−1 indicate the formation
of amorphous carbon structures; these bands allow us to differentiate between the
ET group and, the PV and PMF group. We think that the discrimination is possible
due to changes in concentration of the parent components used in the carbonization
process such as lipids and glycolytic metabolites.
Reactive nonneoplastic subjects are a group of patients whose symptoms mimic
those of MPNs but in turn are not affected by MPN. Importantly, reactive disorders
are not clonal and could arise as a response to poor lung function and high altitude
exposure, among others. We evaluated reactive nonneoplastic subjects as means of
control. Interestingly, this group of patients seem to have lower TEI than MPN
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patients, and for all ratios of intensities, they are in the extreme opposite of controls
values. Further characterization of this group of patients in terms of gene expression
and cellular protein contents will be required for a more complete interpretation of
the data.
We observed a hypoxia-like behavior in granulocytes from MPN patients given
the upregulation of SLC2A1 and the downregulation of PDK1, both glycolytic gene
targets of HIF1. Our conclusions from the spectral data are supported by the
expression measurements on granulocytes as a higher cellular glucose intake will be
necessary for survival, explaining the shift of the background maximum, as well as
the reduction of FAD, which is a consequences of the metabolic transformation [35]
and explains the change in the background maximum.
4.8 Summary
In conclusion, we evaluated the diagnostic potential of normalized integrated
emission and ratios of intensity pairs of the emission spectra from granulocytes of
myeloproliferative disorders patients enhanced by the proximity to silver nanoparti-
cles. We found that the intensity ratios are excellent tests for the presence of MPNs,
and that some ratios were able to discriminate ET from other myeloproliferative
neoplasms. We hypothesized that the spectral changes in data from MPN patients
result from changes in the cellular metabolism that lead to increase glucose uptake
and reduced FAD cellular content; this may explain both the continuum blue shift
and the weakness of the emission background in MPN patients.
We provide additional supporting evidence for dysregulation of the expression of
two genes SLC2A1 and PDK-1 regulated by HIF1 in MPNs patients suggesting that
MPNs, similar to other malignancies, modify their metabolism by the Warburg effect.
Therefore, our data also support the existence of the Warburg effect in MPN, which
likely accounts for our SERS data.
4.9 Acknowledgements
We thank Kimberly Hickman for her invaluable help with samples and patient
coordination, Dr. Nicholas Borys for assistance with time resolved measurements
104
and Dr. Randy Polson for assistance with EDS measurements.
4.10 References
[1] M. Lichtman, Williams Hematology (McGraw-Hill, Medical Pub. Division, New
York, NY, 2006).
[2] P. J. Campbell and A. R. Green, “The myeloproliferative disorders,” New Engl
J Med 355, 2452–2466 (2006).
[3] E. J. Baxter, L. M. Scott, and P. J. Campbell, “Acquired mutation of the tyrosine
kinase JAK2 in human myeloproliferative disorders,” Lancet 365, 1054–1061
(2005).
[4] H. Zhan and J. L. Spivak, “The diagnosis and management of polycythemia vera,
essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era,”
Clin Adv Hematol Oncol 7, 334–42 (2009).
[5] A. M. Vannucchi and P. Guglielmelli, “Molecular pathophysiology of
Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mu-
tations,” Haematologica 93, 972–6 (2008).
[6] C. Krafft, B. Dietzek, and J. Popp, “Raman and CARS microspectroscopy of
cells and tissues,” Analyst 134, 1046–1057 (2009).
[7] M. Moskovits, “Surface-enhanced spectroscopy,” Rev Mod Phys 57, 783–826
(1985).
[8] M. Moskovits, “Surface-enhanced Raman spectroscopy: A brief retrospective,”
J Raman Spectrosc 36, 485–496 (2005).
[9] J. Kim and C. Dang, “Cancer’s molecular sweet tooth and the Warburg effect,”
Cancer Res 66, 8927–8930 (2006).
[10] A. Tefferi and J. W. Vardiman, “Classification and diagnosis of myeloproliferative
neoplasms: The 2008 World Health Organization criteria and point-of-care
diagnostic algorithms,” Leukemia 22, 14–22 (2008).
[11] S. I. Swierczek, N. Agarwal, R. H. Nussenzveig, G. Rothstein, A. Wilson, A. Artz,
and J. T. Prchal, “Hematopoiesis is not clonal in healthy elderly women,” Blood
112, 3186–3193 (2008).
[12] G. Chen and J. Prchal, “X-linked clonality testing: Interpretation and limita-
tions,” Blood 110, 1411–1419 (2007).
[13] J. Prchal, J. F. Prchal, M. Belickova, S. Chen, Y. Guan, G. L. Gartland,
and M. D. Cooper, “Clonal stability of blood cell lineages indicated by X-
chromosomal transcriptional polymorphism,” J Exp Med 183, 561–567 (1996).
105
[14] R. H. Nussenzveig, S. I. Swierczek, J. Jelinek, A. Gaikwad, E. Liu, S. Verstovsek,
J. F. Prchal, and J. T. Prchal, “Polycythemia vera is not initiated by JAK2V617F
mutation,” Experimental Hematology 35, 32.e1–32.e9 (2007).
[15] B. Yeo, T. Schmid, W. Zhang, and R. Zenobi, “A strategy to prevent signal
losses, analyte decomposition, and fluctuating carbon contamination bands in
surface-enhanced Raman spectroscopy,” Appl Spectrosc 62, 708–713 (2008).
[16] A. Otto, “What is observed in single molecule SERS, and why?” J Raman
Spectrosc 33, 593–598 (2002).
[17] G. I. N. Waterhouse, G. A. Bowmaker, and J. B. Metson, “The thermal
decomposition of silver (I, III) oxide: A combined XRD, FT-IR and Raman
spectroscopic study,” Phys Chem Chem Phys 3, 3838–3845 (2001).
[18] M. L. Jacobson and K. L. Rowlen, “The role of O2 in SERS-active thin metal
film photodynamics,” J Phys Chem B 110, 19 491–19 496 (2006).
[19] N. P. W. Pieczonka and R. F. Aroca, “Inherent complexities of trace detection
by surface-enhanced Raman scattering,” ChemPhysChem 6, 2473–2484 (2005).
[20] X. M. Lin, Y. Cui, Y. H. Xu, B. Ren, and Z. Q. Tian, “Surface-enhanced raman
spectroscopy: Substrate-related issues,” Anal Bioanal Chem 394, 1729–1745
(2009).
[21] K. L. Norrod and K. L. Rowlen, “Removal of carbonaceous contamination from
SERS-active silver by self-assembly of decanethiol,” Anal Chem 70, 4218–4221
(1998).
[22] I. Po´csik, M. Veres, M. Fle, S. To´th, and M. Koo´s, “Specific statistical features
of surface enhanced Raman scattering (SERS) spectra of graphite,” J Non-Cryst
Solids 338-340, 496–498 (2004).
[23] S. Potgieter-Vermaak, N. Maledi, N. Wagner, J. H. P. Van Heerden,
R. Van Grieken, and J. H. Potgieter, “Raman spectroscopy for the analysis of
coal: A review,” J Raman Spectrosc 42, 123–129 (2011).
[24] J. Zhao, H. Lui, D. I. McLean, and H. Zeng, “Automated autofluorescence
background subtraction algorithm for biomedical Raman spectroscopy,” Appl
Spectrosc 61, 1225–32 (2007).
[25] J. C. A. Hopkins, G. K. Radda, R. L. Veech, and K. Clarke, “Accumulation of
2-deoxy-D-glucose-6-phosphate as a measure of glucose uptake in the isolated
perfused heart: A 31P NMR study,” Metab Eng 6, 36–43 (2004).
[26] N. J. Borys and J. M. Lupton, “Surface-enhanced light emission from single hot
spots in tollens reaction silver nanoparticle films: Linear versus nonlinear optical
excitation,” J Phys Chem C 115, 13 645–13 659 (2011).
106
[27] J. W. Kim, I. Tchernyshyov, G. L. Semenza, and C. V. Dang, “HIF-1-mediated
expression of pyruvate dehydrogenase kinase: A metabolic switch required for
cellular adaptation to hypoxia,” Cell Metab 3, 177–185 (2006).
[28] G. L. Semenza, “Signal transduction to hypoxia-inducible factor 1,” Biochem
Pharmacol 64, 993–998 (2002).
[29] O. Basturk, R. Singh, E. Kaygusuz, S. Balci, N. Dursun, N. Culhaci, and
N. V. Adsay, “GLUT-1 expression in pancreatic neoplasia: Implications in
pathogenesis, diagnosis, and prognosis,” Pancreas 40, 187–192 (2011).
[30] H. Ito, M. Duxbury, M. J. Zinner, S. W. Ashley, and E. E. Whang, “Glucose
transporter-1 gene expression is associated with pancreatic cancer invasiveness
and MMP-2 activity,” Surgery 136, 548–556 (2004).
[31] T. Kawamura, T. Kusakabe, T. Sugino, K. Watanabe, T. Fukuda, A. Nashimoto,
K. Honma, and T. Suzuki, “Expression of glucose transporter-1 in human gastric
carcinoma: Association with tumor aggressiveness, metastasis, and patient
survival,” Cancer 92, 634–641 (2001).
[32] M. Younes, R. W. Brown, M. Stephenson, M. Gondo, and P. T. Cagle, “Overex-
pression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated
with poor survival,” Cancer 80, 1046–1051 (1997).
[33] M. Younes, D. Juarez, L. V. Lechago, and S. P. Lerner, “Glut 1 expression in
transitional cell carcinoma of the urinary bladder is associated with poor patient
survival,” Anticancer Res 21, 575–578 (2001).
[34] S. Mahajan, R. M. Cole, J. D. Speed, S. H. Pelfrey, A. E. Russell, P. N. Bartlett,
S. M. Barnett, and J. J. Baumberg, “Understanding the surface-enhanced Raman
spectroscopy “background”,” J Phys Chem C 114, 7242–7250 (2010).
[35] J. H. Ostrander, C. M. McMahon, S. Lem, S. Millon, J. Brown, V. L. Seewaldt,
and N. Ramanujam, “Optical redox ratio differentiates breast cancer cell lines
based on estrogen receptor status,” Cancer Res 70, 4759–4766 (2010).
[36] X. J. Liang, A. Q. Liu, C. S. Lim, T. C. Ayi, and P. H. Yap, “Determining
refractive index of single living cell using an integrated microchip,” Sensors
Actuat A-Phys 133, 349–354 (2007).
[37] R. Thar and M. Khl, “Propagation of electromagnetic radiation in mitochon-





Label-free surface enhanced raman spectroscopy for the detection of proteins in
solutions is highly desirable as it would simplify sample preparation and data analysis
for medical screening and diagnostic applications. In this chapter, we describe our
studies related to the application of SERS for the detection of hemoglobin (Hb)
variants and the prediction of subjects’ response to the seasonal influenza vaccine.
5.1 Detection of hemoglobin variants
As described in section 2.5, the detection of Hb variants is not always possible by
the standard electrophoretic or chromatographic methods. Hb variants are molecules
that resemble the normal hemoglobin except for one amino acid substitution. Thus,
differences in mass can be small enough to elude mass spectrometry. Hb variants
are structurally different when compared to normal hemoglobin, and to one another.
So, we propose SERS as an alternative for the detection of Hb variants that has the
potential to differentiate them in a quantitative fashion.
5.1.1 Methods
Whole blood samples were received from ARUP laboratories (Salt Lake City, UT)
and hemolysate was obtained the same day using the protocol described below. In




2 ml of whole blood were diluted in 6 ml of PBS at room temperature. The
solution was centrifuged at 600 g for 10 min, and the supernatant was discarded.
Steps 1 and 2 were repeated at least twice. In between centrifugation steps, blood
was kept on ice. Pellet was diluted in autoclaved distilled water at 4 oC to fill a 15 ml
centrifuge tube up to 10 ml. The dilution stood for 15 min. Samples were centrifuged
at 2000 g for 15 min. The top 5 to 6 ml were collected and transferred to a new tube,
while the rest was discarded.
The confocal microspectroscopy configuration described in Section 3.1.1 was used
for SERS spectra acquisition using a microscope objective of 60X (NA 0.80). Silver
nanoparticles deposited on glass (i.e., substrates) were prepared by the Tollens reac-
tion as explained in Section 3.1.2 with a 120 seconds reaction time. The substrates
were stored for a time period shorter than one day under a nitrogen atmosphere
from the time of preparation until their use. A drop of hemolysate was placed
onto the silver nanoparticles substrate, and a coverslip was place on top, carefully
to avoiding air bubbles. To acquire the SERS spectra, 5 to 6 scans of 25 µm by 25
µm (20 by 20 pixels) per sample were done, collecting 400 spectra per scan. Not
all of the acquired spectra were surfaced-enhanced. Thus, a selection algorithm was
implemented based on the spectral flatness, defined as the ratio of the geometrical








where n is the the number of points per spectrum. Using this criterion, only between
0.1 % and 2 % of the total number of spectra per sample were selected. Selected SERS
spectra were normalized to the total integrated emission and averaged, such that each
sample was represented by one spectrum during principal component analysis (PCA).
PCA is explained in detail in section 3.2.3. Briefly, PCA works as a linear transfor-
mation from the space of variables to a new space that represents the data in a more
meaningful way. This representation has its origin in the center of gravity of the data
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points and has a new basis of which the axes are called principal components(PCs).
PCs lie along the directions of maximum variability in the data. PC1 is the one that
describes most of the variance, followed by PC2, PC3 and so forth. Each data point
in the PCs space is thus represented by a new set of coordinates called scores. Plots of
scores provide relevant information on hidden patterns in the data, such as correlation
or clustering for example. The loadings plot of a PC maps the contributions of each
variable to the PC.
Classification of various Hb variants was explored using support vector machine
(SVM) classification [2]. Briefly, SVM involves the construction of a hyperplane1
in such way that the distance from the closest samples to the hyperplane from two
different classes is maximized; a 2-dimensional (2D) example is shown in Figure 5.1.
Here, SVM is used to show that classification of hemoglobin variants based on the
SERS spectra is possible. The results from the SVM are given as a ‘confusion matrix’
which is explained in Table 5.1. The miss rate defined in equation 5.2 and the positive
predictive value (PPV) and negative predictive value (NPV), are defined in equations
5.3 and 5.4, respectively. Both PCA and SVM computation were done with the The
Unscrambler X software [3].
Miss Rate =
Number of miss assigned cases
Total number of cases
× 100 (5.2)
PPV =
Number of true positive cases
Total number of positive cases
× 100 (5.3)
NPV =
Number of true negative cases
Total number of negative cases
× 100 (5.4)
Low PVV or NPV indicate a high number of cases being incorrectly assigned as
positive or negative cases, respectively. In the case of low PPV, follow up tests are
necessary to confirm a positive outcome, whereas for low NPV, additional tests are
1The hyperplane of a n-dimensional space is a subspace with n-1 dimensions that divides
the space in two.
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Figure 5.1: The principle of support vector machine (SVM) classification techniques
is exemplified here. For a 2D space the hyperplane is a straight line, but only one
hyperplane, H2 in this case, maximizes the distance from it to the closest samples in
both groups.
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required to confirm negative result. Screening test refers to tests that generally have
either high PPV or NPV, but not both.
5.1.1.2 Silver nanoparticles colloid
In addition to the measurements performed using the Tollens substrate, measure-
ments on standard, normal human hemoglobin were done. The silver colloid substrate
was prepared according to published protocol [4]. Briefly, 0.1 mM of aqueous silver
nitrate was heated to 98 oC, at which point 2 ml of 1 % Trisodium Citrate solution
were added. The mixture was kept at constant temperature of 98 oC for 60 min, and
special care was taken to prevent the mixture from boiling. In the case of colloidal
nanoparticles, aggregation agents are required to maintain a short distance between
the analyte and the metal nanoparticles. We used the aggregation agent reported by
Han et al. [5]. The aggregation agent is 0.1 M aqueous solution of sodium sulfate
with pH of 3 which was adjusted using sulfuric acid.
A solution of hemoglobin in water was prepared and mixed in a 1:10 ratio with
the aggregation agent. The Hb/aggregation agent was mixed with a 1:5 volume ratio
with the silver nanoparticles colloid. The SERS measurements were done immediately
following the preparation procedure.
5.1.2 Results and discussion
Figure 5.2B shows the SERS spectrum of hemoglobin excited with a 488 nm argon
laser and a power of 0.5 mW. For comparison the Raman spectrum of hemoglobin
excited with 514.5 nm laser is also shown (Figure 5.2A). Notice that the vibrational




Figure 5.2: Spectra of hemoglobin. A: Normal Raman spectrum excited at λexc =
514.5nm. Reprinted with permission from [6]. Copyright 2001 by SPIE. B: Measured
SERS of hemoglobin excited at λexc = 488nm on Tollens substrate.
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cm−1 and 1491 cm−1 are barely visible in the regular Raman spectrum. This is due to
adsorption of the hemoglobin onto the silver, which in turn changes the Raman cross-
section of the molecule, and the proximity to the nanoparticles selectively enhances
some of the vibrational bands [7].
Hb variants are structurally different. The differences arise from a single amino
acid substitution in the protein. Since the difference is structural, SERS is expected
to be able to discriminate among various Hb variants. This could successively help
the diagnosis of those variants which elude other techniques, as explained before. To
prove the ability of SERS to discriminate Hb variants, samples from patients affected
with Hb E [8], Hb S [9], Hb C [10] and traits FE and FS were analyzed as follows.
The results are shown in Figures 5.3 through 5.5, where the scores plots and the
corresponding loading plots are shown. Figure 5.3A shows that Hb variants S and C
can be discriminated based on PC1 and PC2 scores, which together explain 98% of
the variability in the data set. Figure 5.3B and 5.3C show that a large part of the
variability in the case of Hb S and Hb C, is explained by the spectral features in the
1400-1800 cm−1 region and peaks at 1603 cm−1. SVM analysis was done on the data
sets shown in Figures 5.3A, 5.4 and 5.5. The results are shown in Table 5.2. For the
case of hemoglobin E and traits FS and FE, even though a visible separation is clear
in Figure 5.5B, SVM results were poor and have a miss rate of 71 %. On the other
hand, when the only FE sample was taken out of the data set, the miss rate improved
to 17 %.
These results provide evidence that SERS can distinguish between different vari-
ants of hemoglobin. In addition, we also explored silver nanoparticle colloid as means
for Raman scattering enhancement. Figure 5.6A shows SERS spectra from standard
human hemoglobin measured using a 488 nm argon laser at a power of 0.5 mW.
Characteristic spectral features of hemoglobin are shown in the region between 1300
and 1700 wavenumbers. The features in the region 800-1000 cm−1 arise from the
aggregation agent and the silver colloid, whereas the broad band at ∼500 cm−1 is
attributed to silver oxides [11] as they are observed from the colloid/aggregation





Figure 5.3: PCA for Hb variant S (green) and Hb variant C (red). A: Scores plot





Figure 5.4: Scores plots of A: PC4 vs. PC3 for Hb variant S (green) and Hb variant




Figure 5.5: Scores plots of A: PC7 vs. PC3 for Hb variants C(green), Hb E(red) and
Hb S(blue) and B: PC7 vs. PC3 for Hb E(green) and traits FS(red) and FE(blue).
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Table 5.2: SVM results for hemoglobin variants. The ‘miss rate’ is defined in
equation 5.2.
Data Set No. False Cases Total Cases Miss Rate
Hb E, Hb C 1 9 11%
Hb E, Hb S 1 8 12.5%
Hb S, Hb C 1 9 11%
Hb E, Hb C, Hb S 3 13 23%
Raman scattering spectra from crystalized hemoglobin (acquired by Xu et al), and
hemoglobin/silver aggregates in solution excited with 514.5 nm laser wavelength at
1 mW and 1 µW of excitation power, respectively. It is evident that SERS is not
observed in this case, possibly because single silver nanoparticles are not as good for
enhancement of the Hb Raman spectrum, and/or the concentration of Hb is too high,
thus recovering bulk Hb Raman [12]. Very low concentrations of hemoglobin were
tried, and similar spectra to the one shown in Figure 5.6A were obtained. Failed
SERS measurements have been also reported in ref. [13]. Xu et al. reported single
hemoglobin molecule SERS from deposited mixtures of silver nanoparticles colloid
with very low concentrations of hemoglobin [12]. These results suggest that SERS
measurements from hemoglobin using colloidal silver nanoparticles in solution are not
feasible.
5.2 Seasonal influenza response3
Chronic heart failure (CHF) is considered a high-risk condition for influenza illness.
Vaccination against influenza infection results in decreased cardiac related hospital
admissions, a reduction in acute heart failure exacerbations, and is known to decrease
all cause mortality [14]. Older adults, and persons of all ages with cardiac disease
or other co-morbidities and treatments that render them immune-compromised, are
known to be at greater risk for influenza infection despite being vaccinated due to
reduced antibody and cell mediated responses to vaccines [15, 16]. Studying the
3This project was done in collaboration with Professor Orly Vardeny from the School of




Figure 5.6: SERS spectra of hemoglobin. A:Raman spectrum from a mixture
of hemoglobin and silver nanoparticles colloidal acquired using 488nm excitation
wavelength at 0.5mW power. B: Spectra from crystalized hemoglobin (I) and
hemoglobin/silver aggregates in solution (II) with 514.5nm excitation wavelength and
1mW (I) and 1µW (II) excitation power, respectively. Reprinted with permission
from [12]. Copyright 1999 by the American Physical Society.
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response to the influenza vaccine within this population is of medical relevance since
the results may contribute to the future planning in vaccination strategies. The usage
of SERS, Raman scattering and autofluorescence spectroscopies may contribute to the
advancement of new research and diagnosis technologies.
Immunoglobulins (Igs), i.e., antibodies, are proteins found in the blood and body
fluids that are part of the immune system and help recognize foreign objects, such
as viruses and bacteria. Antibodies are secreted by B-cells in the blood, which can
produce as many as 1014 different antibodies. In contrast, an antigen is a molecule
that distinguishes the foreign object. Thus, when the foreign object enters the body
it is recognized by antibodies, consequently triggering the immune system response.
The antibody recognizes the antigen through a highly specific binding process called
‘induced fit ’. Specific antibodies are used as indicators of bacterial or viral infections,
as well as a measure for response to vaccines. Enzyme-linked immunosorbent assay
(ELISA) is a widely used method to detect antibodies. Additional methods used are
chemiluminescence assay, enzymed-linked fluorescence assay and indirect immunoflu-
orescent assay. All of these methods provide high sensitivity and specificity. However,
these methods are not sufficiently fast because of very specific and multiple sample
preparation steps [17,18].
Recently, it has been shown that SERS allows detection of antibodies in human
colostrum [19] and human serum [20], as well as antibody-antigen interaction [21].
Based on these findings, heart failure patients are expected to show different spectra
than age-matched controls when measured on blood serum, due to differences in
concentrations of antibodies.
In the present study SERS measurements are demonstrated to correlate with a
positive/negative response to the seasonal influenza vaccine. Measurements were done
on samples collected before and after influenza vaccine administration and provided
by Dr. Orly Vardeny from the University of Wisconsin-Madison.
5.2.1 Methods
Serum samples were obtained from CHF patients and healthy subjects before and
after seasonal influenza vaccination. Sample collection was done at the University of
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Wisconsin-Madison, and the project underwent review by IRBs at both institutions.
Before and after vaccination serum samples were analyzed by ELISA method, and
determination of a positive or negative response based on differences in antibody
concentrations pre- and postvaccination was made [22]. Confocal microspectroscopy
was used to acquire emission spectra under the same conditions as described in section
5.1.1. A drop of serum diluted with a ratio of 1:1 in ultra pure water was placed onto
the Tollens substrate, and a coverslip placed on top. The spectra selection criteria
were given by spectral flatness, eq. 5.1, as described above. After selection, the
average spectra were calculated per subject, before and after vaccination. Average
SERS spectra were analyzed using PCA and SVM (sections 3.2.3 and 5.1.1).
5.2.2 Results and discussion
The ability of SERS to differentiate among subjects who responded to the vaccines
from those who did not was tested. SVM analysis was done on the the first 7 principal
components, which together explained 100 % of the variability within the data. PCA
and subsequent binary classification among responders and nonresponders was done
within the subpopulations as described in Table 5.3.
For the first group, that is all subjects before vaccination, false positives were not
observed. On the other hand, NPV was 75%. This result implies that SERS on serum
can distinguish whether a subject will respond to the vaccine. PPV and NPV had the
same values after vaccination as they did before vaccination, i.e., 100 % and 75 %,
respectively. When SERS spectra were analyzed exclusively from CHF patients, PPV
and NPV were 100% and 71.4%, respectively, for both pre- and postvaccination. The
Table 5.3: Subpopulations and groups defined therein used for PCA and subsequent
SMV analysis of SERS spectra of human serum
Analysis Subpopulation
1 All subjects before vaccination
2 All subjects after vaccination
3 CHF Patients before vaccination
4 CHF Patients after vaccination
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distinction between responders and nonresponders is depicted in Figure 5.7, which
shows the scores plot of PC2 vs PC1 of CHF patients’ spectra after vaccination.
These results open the possibility for a screening test that will allow prediction
of response to seasonal influenza vaccines, which in turn could help to improve the
care management in CHF patients. In addition, using a different approach for data
analysis such as regression methods, SERS has the potential of measuring specific
antibodies, such as in this case, those associated with the influenza strains included
in each year’s vaccine. Similar experiments have shown that it is possible to measure
the concentration of various chemicals in blood serum and urine by normal Raman
scattering [23]; to detect clenbuterol using SERS in conjunction with functionalized
nanoparticles [24]; to detect of buserelin with a technique that combines SERS and
electrophoresis techniques and allows a limit of detection as low as picomols per liter
in highly complex samples, such as body fluids [25]; and to classify blood serum from
subjects that are either hepatitis C positive or negative based on SERS.
SERS measurements on hemoglobin variants and pre- and postseasonal influenza
vaccination blood serum demonstrate the ability of this technique in combination
with multivariate statistical analysis and classification algorithms to separate and
distinguish blood samples with a variety of different characteristics.
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CHAPTER 6
SUMMARY AND FUTURE DIRECTIONS
6.1 Summary
Autofluorescence, Raman scattering and SERS, among other optical techniques,
have been proven to be promising tools for medical diagnosis and biological sens-
ing [1–9], providing high sensitivity and specificity as well as fast and relatively
simple implementation strategies. This work encompasses the development of medical
diagnostic tools based on fluorescence and SERS that have the potential of greatly
benefiting the care management of people affected with myeloproliferative disorders,
hemoglobinopathies and chronic heart failure.
6.1.1 Myeloproliferative neoplasms
MPNs are hematological malignancies due to clonal proliferation that arises from
somatic mutation of a single stem cell. These diseases result in clonal granulocytes and
other circulating blood cells that are often difficult and expensive to differentiate from
reactive cells as well as from congenital disorders caused by germline mutations. We
presented an evaluation of SERS spectroscopy for differentiation of MPN granulocytes
from controls. We found that several spectral ratios of the background fluorescence in-
tensity that accompanies the SERS spectra of granulocytes serve as excellent markers
for the presence of MPNs. In addition, the total emission intensity obtained from the
normalized area under the SERS spectrum is also a good marker for MPNs, although
‘specificity’ and ‘sensitivity’ are lower than those obtained using the intensity ratios.
We found expression dysregulation of two HIF-regulated genes, namely SLC2A1 and
PDK1, which correlate with our results obtained by SERS assay in MPN patients
and support the presence of the Warburg effect in clonal granulocytes.
We hypothesized that SERS measures metabolic change in granulocytes through
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two possible mechanisms: (i) Changes in dielectric properties of the environment
surrounding the silver-cell interface; and (ii) changes in flavin adenine dinucleotide
concentrations, which in turn changes the relative contribution of the autofluorescence
to the emission spectrum. These hypotheses are supported by SERS measurements of
2-deoxy-D-glucose incubated granulocytes where the emission spectra show a similar
behavior as to that observed in the SERS spectra of controls and patients.
6.1.2 Hemoglobinopathies and chronic heart failure
Label-free SERS for the detection of proteins in solutions is highly desirable as
it may simplify sample preparation and data analysis for medical screening and
diagnostic applications. We presented applications of SERS towards the detection
of hemoglobin variants, and screening of CHF patient who might not respond to the
seasonal influenza vaccine.
Hemoglobin variants are molecules that resemble the normal hemoglobin except
for one amino acid substitution. Common methods used for the detection of Hb
variants are electrophoresis and chromatography and recently, mass spectroscopy [10].
Some Hb variants elude all methods, making proper diagnosis rather difficult. We
proposed SERS as an alternative for Hb Variant detection and we obtained excellent
results. We were able to discriminate among Hb variants S, C and E as well as traits
FS and FE using classification techniques such as supporting vector machine.
Older adults, and persons of all ages with cardiac disease or other co-morbidities
and treatments that render them immune-compromised, are known to be at greater
risk for influenza infection despite being vaccinated due to reduced antibody and cell
mediated responses to vaccines [11,12]. Studying the response to the influenza vaccine
within this population is of medical relevance since the results may contribute to the
future planning in vaccination strategies. We proposed SERS as a technique for the
screening of responsive and nonresponsive patients to the seasonal influenza vaccine.
Based on multivariate analysis of SERS spectra, we were able to distinguish those
subjects who did not respond to vaccine, even before the vaccination. This technique
has the potential to inform health care practitioners of people who are at risk of
not responding to the influenza vaccine and therefore take the necessary precautions.
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Moreover, SERS has great quantitative capabilities as demonstrated by work done
on body fluids by other research groups [7–9,13–15]. Refinement of the strategy used
for this work could lead to detection, as well as quantification, of specific antibodies.
6.2 Future directions
As for every research project many questions emerged as we learned more about
the techniques and their capabilities. Here we propose some projects that could follow
up the work described in this thesis.
In general, all the projects would benefit from larger sample statistics, especially
the tests that involved hemoglobin variant detection and CHF patient screening. A
larger sample size would not just help to improve the confidence in the results, but
would allow the construction of regression models that in turn could be used for
quantitative sensing of hemoglobin and/or antibody concentration. A comprehensive
survey of hemoglobin variants that includes not only the common ones (like S and
C) but also those that elude the usual techniques, such as Hb Lepore, would increase
the impact of the proposed technique.
In the case of myeloproliferative neoplasms, there are interesting projects that
would nicely complement the results presented here. First is to find the spectral
differences between MPN and reactive non-MPN conditions as well as identifying their
origin. This includes both SERS and DNA expression measurements. In addition,
a broader population that includes myeloid leukemia patients, to test the capability
of SERS to discern between MPN patients and leukemia patients, would expand the
applicability of SERS spectroscopy.
An immediate step for MPN diagnosis using SERS would be to develop regression
models that allow a blind diagnosis of samples. A first step towards this goal was
developed in Chapter 4 with the use of ROC curves that led to the definition of
thresholds that optimized both sensitivity and specificity. However, more robust
models like partial least square regression or neural networks could be implemented.
Such models would need to be tested in a blind experiment.
Another possibility for broadening the scope of the research presented here may be
that of substrate optimization. Many techniques are currently available to synthesize
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nanoparticles in more controlled ways than that of the Tollens reaction. For example,
lithography techniques allow for manufacturing of patterned substrates. A highly
reproducible substrate will contribute to better reproducibility of the measurement,
and consequently it would increase the overall performance of the technique.
Finally, the broad background emission described in Chapter 4 has been inter-
preted as enhanced fluorescence from certain cellular components. However, similar
background spectra are observed from other SERS measurements, even at the single
molecule level where quenching of the fluorescence is expected. A better understand-
ing of the origins of the SERS background from cells would be a an important step
towards the development of new and better sensing application schemes for SERS
and other surface-enhanced optical processes.
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